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Abstract 
 
The drug-to-carrier ratio has been a considerable issue in the design of a drug carrier, 
because the use of unreasonably high quantities of carrier can lead to problems associated 
with carrier toxicity, metabolism and elimination [1]. However, if the carrier itself displays 
therapeutic effects, the drug-to-carrier ratio would no longer be a concern, and the delivery 
system should attain greater therapeutic effects from both the drug and the carrier. 
Epigallocatechin gallate (EGCG), a major ingredient of green tea, has been recognized as an 
attractive functional compound due to its various potential therapeutic effects, including 
anticancer effects [2-9]. Herein we design the core-shell micellar nanocomplex (MNC) 
spontaneously constructed by self-assembly from the EGCG derivatives and proteins. This 
system achieved a greater anticancer effect in vitro and in vivo when loaded with an 
anticancer protein, as compared to the native protein or the carrier alone. This unique green 
tea-based MNC is the first nanoparticle drug delivery system that takes advantage of the 
beneficial bioactivities of EGCG. 
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Chapter 1 – Introduction 
 
1.1. Cancer therapy 
Cancer is a term used for diseases in which abnormal cells divide without control and 
are able to invade other tissues [10]. Normal cells grow and divide in a controlled manner and 
die when they are old or damage, cancer cells grow and divide uncontrollably forming a mass 
of tissue called tumor (Figure 1-1). Today, there are over 200 different types of cancer known. 
 
  
Figure 1-1 Growth of normal and cancer cells. 
 
Cancer is a worldwide medical problem. Statistics by Cancer Research UK reported 
an estimate of 12.7 million new cases of cancer occurred worldwide in 2008 [11]. If this trend 
continues, it is estimated that there will be 22 million new cases of cancer each year by 2030. 
The mortality caused by cancer is 13% of all death worldwide. An estimated 7.6 million 
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people died from cancer worldwide in 2008. In UK alone, 325,000 people were diagnosed 
with cancer and 157,000 cancer deaths occurred in 2010. From all the cancers diagnosed, 
lung cancer is the most common cancer in men and breast cancer is the most common cancer 
in women. Although breast cancer is not the top leading death-causing cancer, it is by far the 
most commonly diagnosed cancer type. The lifetime risk of being diagnosed with breast 
cancer is 1 in 8 women in UK. Thanks to the advance in medical technology in recent years, 
more than three quarters of women diagnosed with breast cancer survive the disease for ten 
years or more. One of the major contributors to the medical technology advancement is the 
use of nanotechnology in devising new treatment strategies leading to better outcome in 
cancer treatment. These include development of nanoscale drug delivery systems (e.g. 
liposomes and polymeric micelles) and new drug therapies (e.g. monoclonal antibodies). 
Generally cancers are treated in a variety of ways depending on the type of cancer, 
stage of the disease and health status of the patient. Common treatment methods are surgery, 
radiotherapy, chemotherapy, hormone therapy and biological therapy. 
 
1.1.1. Surgery 
Surgery is the resection of the tissues from the body. Cancer surgery in particular can 
be performed as part of diagnostic or treatment regimen. According to Mayo Clinic, cancer 
surgery is usually performed to achieve certain objectives [12]. The first objective is cancer 
prevention. High risk individual will be recommended by the doctor to remove part of the 
tissues for cancer screening before cancer develops. For instance, an individual with genetic 
history of familial adenomatous polyposis is at high risk of developing colon cancer. 
Therefore, doctor may recommend the removal of colon and rectum of this individual with 
surgery. The second objective is diagnosis and staging. Tumor tissue of a patient would be 
removed for analysis to diagnose if the tumor is benign or malignant. Malignant tumor could 
Chapter 1: Introduction 
 
 4 
 
then be further classified to different stages of cancer. The third objective is treatment. 
Patients with localized tumor development that has not spread are treated with cancer surgery 
by removing the cancerous tissues. Generally there is no side effect caused by cancer surgery 
unlike other treatment methods like chemotherapy or radiotherapy. However, surgery is a 
local treatment and is only limited to cancer at early stage that is localized and has not spread. 
Since surgery is physical removal of the cancerous tissue, 100% removal of cancer cells is 
not easy. Adjuvant treatments such as chemotherapy and radiotherapy usually follow the 
surgery to remove the remaining cancer cells. Surgery is also not suitable for certain cancer 
type such as leukemia and lymphoma.  
 
1.1.2. Chemotherapy 
Chemotherapy is the cancer treatment by means of cancer drugs which are toxic to the 
cells. Chemotherapy can be administered as a single agent or as a combination of drugs or in 
combination with other treatment methods such as radiotherapy or post-surgery treatment. 
Chemotherapy usually targets the dividing cells and cause cell death. Apart from the cancer 
tissues, some of the healthy tissues of human body are constantly dividing like hair follicles, 
skin, bone marrow and linings of the digestive system. Since chemotherapy kills dividing 
cells, these healthy tissues are also affected and hence side effects of chemotherapy. The most 
common side effects of chemotherapy are tiredness, nausea, diarrhea, constipation, headache, 
fever and falling of hair. Some of the side effects may be mild; others can be serious such as 
damage to the healthy organs including kidney, liver, heart and lung. 
Doxorubicin (DOX) is one example of chemotherapy drug. It is used for the treatment 
of many types of solid cancers. Despite DOX potency, its clinical use is limited due to its 
severe side effects, the most serious being cardiotoxicity [13, 14]. To reduce the 
cardiactoxicity, drug delivery system can be introduced. A new formulation of DOX, 
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pegylated liposomal doxorubicin (Doxil), has been shown to reduce clinical cardiotoxicity in 
patients [15]. 
 
1.1.3. Radiotherapy 
Radiotherapy is the use of radiation to treat an illness. Radiotherapy destroys the 
cancer cells in the treated area by damaging the DNA within these cells. Radiotherapy can be 
given alone or in combination with other treatment regimens such as chemotherapy or 
surgery. When radiotherapy is given together with chemotherapy, it is termed as 
chemoradiation. Radiotherapy may be given as adjuvant to surgery as a pre-surgery 
procedure or post-surgery procedure. Because of the size, some of the tumor may need to be 
irradiated to shrink it prior to surgery. Post-surgery radiotherapy is given to remove any 
remaining cancer cells after the surgery. 
There are two types of radiotherapy: (1) external radiotherapy, whereby the source of 
radiation is external, using X-rays, cobalt irradiation, electrons and protons; and (2) internal 
radiotherapy, whereby the source of radiation is internal, by ingesting radioactive materials 
such as strontium and iodine. Since healthy cells in the treatment area are also damaged by 
the radiation, radiotherapy also causes side effects. Common side effects caused by 
radiotherapy include fatigue, anaemia, hair loss, skin soreness, weight loss and diarrhea. 
 
1.1.4. Hormone therapy 
A hormone is a chemical substance produced in particular parts of the body by 
specific cells, glands, and/or tissues and then transported by the bloodstream to other parts of 
the body where it exerts functional effects, such as the processes of digestion, metabolism, 
growth and reproduction. It can also promote tumor growth. Hormone therapy in cancer is the 
use of medication to block the effects of the hormones and control the cancer progression. 
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Hormone therapy is usually accompanied with a series of side effects including fatigue, 
digestive system problems, menopausal symptoms, mood swings, depression and etc. 
Tamoxifen is one example of hormone therapy for breast cancer treatment, especially 
for estrogen receptor (ER) positive patients. It works by blocking the estrogen receptors and 
inhibits the tumor growth. Studies have demonstrated its therapeutic benefit either used alone 
or in combination with chemotherapy to treat advanced breast cancer [16, 17]. Fisher et al. 
demonstrated that tamoxifen decreased the incidence of invasive and non-invasive breast 
cancer and suggested the use of tamoxifen for prevention of breast cancer. However, the use 
of tamoxifen as breast cancer treatment increased the risk of patient for endometrial cancer 
[18]. 
 
1.1.5. Biological therapy 
Biological therapy is a relatively new strategy in treating cancer as compared to the 
other cancer treatment methods described above. Biological therapy is a targeted therapy and 
acts on processes in cells to inhibit cell growth and division, kill the cells and induce immune 
attack on the cancer cells. This treatment method includes: monoclonal antibodies (mAb), 
cancer vaccines, immunotherapy and gene therapy. 
 
1.1.5.1. Monoclonal antibodies (mAb) 
Monoclonal antibodies are designed to recognize and attach to specific proteins on the 
surface of cells. They work in different ways depending on the protein they are targeting.  
Therefore, different monoclonal antibodies have to be made to target different types of cancer. 
Some of the FDA approved monoclonal antibodies treatments are: 
 Herceptin (trastuzumab, Genentech) for the treatment of HER2-overexpressing metastatic 
breast cancer (MBC) 
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 Rituxan (rituximab, IDEC Pharmaceutical) for the treatment of CD20-posiitve non-
Hodgkin‟s lymphoma 
 Avastin (bevacizumab, Genentech) for the treatment of metastatic non-small-cell lung 
cancer and metastatic colorectal cancer by blocking vascular endothelial growth factor 
(VEGF) 
 
1.1.5.2. Cancer vaccines 
Vaccines are proteins derived from viruses, bacteria or cancer cells that are incapable 
of causing the disease and serve as a protection against the disease. There are two main types 
of cancer vaccines: prevention vaccines and treatment vaccines. Cancer vaccines prevent the 
development of cancer in certain high risk individuals as well as treat the cancer. There is 
only one type of vaccines currently used in clinic for the prevention of cancer: human 
papilloma virus (HPV) vaccine. It prevents cervix cancer by warding against HPV infection. 
 
1.1.5.3. Immunotherapy 
Immunotherapy refers to interferon and interleukin treatment that boost the immune 
system. Both interferons and interleukins belong to the cytokine family. Examples of 
immunotherapy agents would be interferon-α (IFN- α) and interleukin-2 (IL-2), which are 
approved for the treatment of renal cell cancer. Although the exact mechanism of action of 
cytokines is unknown, the effect of the drugs on the cancers cells is indirect. The cytokines 
bind to their specific receptors and initiate intracellular and intercellular signaling cascades. 
Interleukin-2 (IL-2) is a potent stimulator of T-cell proliferation, and if antitumor T cells are 
present, they could be stimulated. The consequence of this action is that tumor-specific 
cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and possibly the subset of these 
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that are intratumoral (tumor infiltrating lymphocytes) are activated, and these leukocytes then 
kill the cancer cells [19]. 
 
1.1.5.4. Gene therapy 
Gene therapy is defined as the treatment of medical disorders by the delivery of 
therapeutic genes into the appropriate cellular targets [20]. These therapeutic genes should 
correct deleterious effects from specific gene mutations in the appropriate cell types or tissues. 
For successful gene therapy, the exogenous therapeutic gene has to be specifically, efficiently, 
and stably incorporated into the target cell. Until today, gene therapy is still in development 
stage. 
 
1.2. Nanotechnology in drug delivery for cancer therapy 
1.2.1. Introduction 
Nanotechnology is the science of engineering materials and systems in the nanometer 
size range, typically 1 – 100 nm [21]. Nanomedicine is considered to be a subdiscipline 
within nanotechnology and is defined as the application of nanotechnology to medicine [22-
25]. Nanomedicine encompasses bioimaging, drug delivery systems and new drug therapies 
[26]. Here the application of nanomedicine in cancer therapy will be the subject of the topic. 
Nanotechnology in bioimaging usually involves the use of semiconductor quantum 
dots (QDs) which is usually in the size of 1 – 10 nm with unique photochemical and 
photophysical properties. These include improved brightness as compared to organic dyes, 
resistance against photobleaching and multicolor fluorescence emission. By altering the QDs 
size and the chemical composition, the fluorescence emission can be controlled spanning a 
broad wavelength range of 400-2000 nm [27]. This technology is beneficial for detection and 
diagnostic of cancers. 
Chapter 1: Introduction 
 
 9 
 
Nanotechnology has a great impact in drug delivery by altering the biodistribution and 
pharmacokinetics of the therapeutics [28-37]. The majority of cancer drugs are hydrophobic 
and have poor water solubility. This limits their efficacy due to poor bioavailability. Drug 
carriers enable solubilization of the poorly soluble drug with the use of nanosuspension [38]. 
Encapsulating the drugs in the drug carrier, such as liposomes (lipid based nanocarrier), 
keeps the drugs in circulation for a longer period of time and hence improve therapeutic 
efficacy [39, 40]. The development of nanoparticles for drug delivery has reduced the side 
effects due to the treatment toxicity. The bioavailability of the anticancer drugs in 
chemotherapy would also be improved and enabled the reduction of treatment dose which 
further reduce the toxicity [41].  
Nanotechnology has enabled the discovery of new therapies for cancer. One of the 
examples would be the development of monoclonal antibodies [26]. The use of antibodies as 
therapeutics was made possible by overcoming the immunogenicity problem of mouse 
monoclonal antibodies by chimerization and humanization of the mouse antibodies [42]. Up 
to date, 12 or more monoclonal antibodies have been approved by FDA for clinical use in 
cancer [43]. The mechanism of action includes inhibition of receptor signaling and function, 
antibody-dependent cellular cytotoxicity, direct induction of apoptosis, complement 
dependent cytotoxicity, delivery of toxic payload and a combination of the various 
mechanisms. 
Common treatment methods for cancer are surgery, radiotherapy and chemotherapy. 
Chemotherapy and radiotherapy carry a substantial risk of toxicity. Treatment goals for 
cancer would either be cure, control or palliation depending on the disease stages. Radical 
and aggressive therapy would be given to the patients having reasonable chances of being 
cured. Palliative therapy would be used if the patient‟s condition is beyond cure with the 
intention of minimizing the excessive toxicity of the therapy. However, it‟s difficult to 
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determine the point to change the treatment strategy from aggressive to palliative. 
Nanotechnology in medical application is promising to solve this problem.  
 
1.2.2. Important concepts in nanocarriers for cancer therapy 
There are several important concepts in nanocarriers for cancer therapy: enhance 
permeability and retention (EPR) effect, nanocarrier clearance by mononuclear phagocyte 
system (MPS), and optimal nanocarrier characteristics for cancer applications [44]. 
 
1.2.2.1. Enhanced permeability and retention effect 
The concept of enhanced permeability and retention (EPR) effect was first introduced 
by Maeda and Matsumura in 1986 [45]. They demonstrated that macromolecules 
accumulated in the tumor tissue for prolonged period with little lymphatic recovery. EPR 
effect is attributed to two factors: the disorganized pathology of angiogenic tumor vasculature 
with its discontinuous endothelium, leading to hyperpermeability to circulating 
macromolecules, and the lack of effective tumor lymphatic drainage, which leads to 
subsequent macromolecular accumulation (Figure 1-2). 
Normal vasculature is typically 8 – 10 μm in diameter and uniformly structured, while 
tumor vasculature has high variation in vessel diameter ranging from 20 to 100 μm with 
highly chaotic organization and branching and leaky walls [46]. The incomplete tumor 
vasculature results in leaky vessels with gap sizes of 100 nm to 2 μm [47]. The leaky tumor 
vasculature enables the accumulation of macromolecules or nanocarriers. In normal tissues, 
macromolecules are cleared by lymphatic system. However, tumor tissues are characterized 
by impaired lymphatic system. Proliferating tumor cells compress lymphatic vessels and 
collapse most of the vessels, especially at the center of tumors. Therefore the accumulated 
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macromolecules or nanocarriers are retained in the tumor for extended period of time. The 
impaired lymphatic drainage coupled with leaky tumor vasculature result in the EPR effect. 
 
 
Figure 1-2 Schematic representation of different mechanisms by which nanocarriers 
can deliver drugs to tumors. Polymeric nanoparticles are shown as representative 
nanocarriers (circles). Passive tissue targeting is achieved by extravasation of nanoparticles 
through increased permeability of the tumor vasculature and ineffective lymphatic drainage 
(EPR effect). Active cellular targeting (inset) can be achieved by functionalizing the surface 
of nanoparticles with ligands that promote cell-specific recognition and binding. The 
nanoparticles can (i) release their contents in close proximity to the target cells; (ii) attach to 
the membrane of the cell and act as an extracellular sustained-release drug depot; or (iii) be 
internalized into the cell. Figure reproduced with permission from [50]. Copyright (2007) 
Nature Publishing Group. 
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1.2.2.2. Nanocarrier clearance by the Mononuclear Phagocyte System 
Drug delivery system or nanocarriers are required to have long circulation in vivo to 
take full advantages of the EPR effect. However, nanocarriers are prone to clearance by the 
mononuclear phagocyte system, also known as the reticuloendothelial system [44, 48]. MPS 
cells can interact with nanocarriers and lead to their opsonization. Since premature 
elimination from circulation will prevent nanocarriers from accumulating in tumors, much 
effort has been devoted to creating “stealth” nanocarriers. The most common strategy has 
been modifying their surface with hydrophilic polymers, such as polyethylene glycol (PEG) 
[39, 49]. The presence of PEG or other molecules enables steric stabilization, preventing 
protein adsorption, interactions among particles and interactions with immune cells. 
 
1.2.2.3. Optimal nanocarrier characteristics for cancer therapy 
Numerous studies have suggested that nanocarrier size is one of the major factors 
affecting the delivery of the drug [51-53]. Depending on the tumor type, optimal permeation 
into the tumor would require particle of different sizes. Generally, particles smaller than 100 
nm have high permeation into tumors. Sizes also affect the nanocarrier intracellular 
trafficking, which in turn affect its accumulation in the tumor [44]. 
Apart from size, the surface charge of the nanocarrier is another major factor affecting 
the uptake. Positively charged particles are rapidly internalized by cancer cells, while 
negatively charged particles are not favored for cellular uptake [51]. However, the positively 
charged particles trigger immune reactions. Therefore neutral and negatively charged 
nanocarriers are favourable for clinical application [44]. 
The shape of the nanocarriers also plays an important role in the cellular uptake. 
Gratton et al. demonstrated that rod-like particles (high aspect ratio) were more rapidly 
uptaken and internalized by HeLa cells [51]. Huang et al. confirmed this observation by 
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showing that particles with higher aspect ratio were taken up in larger amount and had faster 
internalization rates [54].  
 
1.2.3. Current nanotechnology therapeutics delivery platforms 
Over the past three decades, many nanotechnology therapeutic delivery platforms 
have been developed [55-60]. These include: liposomes, polymeric micelles, dendrimers, 
metal nanoparticles, nanoparticle albumin-bound (nab) technology. These delivery platforms 
will be described in the following section considering the advantages and disadvantages of 
each platform. 
 
1.2.3.1. Liposomes 
Liposome was first described in 1965 [61, 62]. Liposomes are defined as spherical, 
self-closed structures formed by one or more concentric lipid bilayers with an encapsulated 
aqueous phase in the center and between the bilayers [63]. Liposomes have been widely used 
in the clinical settings due to their advantages including their biocompatibility and 
biodegradability, ability to protect the drugs from degradation and reduce the side effects of 
the drugs, and flexibility to form different lipid drug delivery vehicles based on the lipid 
molecular structure [63, 64]. Apart from the stealth liposomes formulation, many liposomes 
have the problem of rapid clearance by the MPS. 
Liposomal anthracyclines were the first nanoparticle therapeutics approved for 
clinical use. Anthracyclines are a class of antibiotic drugs used for chemotherapy derived 
from Streptomyces bacteria. Doxorubicin is the most commonly used anthracyclines. 
Pegylated liposomal doxorubicin (PLD) (Doxil, Caelyx) is a liposomal formulation of 
doxorubicin. Pharmacokinetics is drastically altered with a circulation half-life of 2–3 days 
for PLD versus less than 5 min for doxorubicin [41]. 
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Despite the extensive use in clinical settings, liposomes are not without limitation. 
Some of the limitations of liposomes are stability issues, batch to batch reproducibility, 
sterilization method and low drug entrapment [65]. One of the major issue to the use of 
liposomes as drug carrier is the chemical and physical instability of liposomes. Liposomes are 
prone to degradation due to the hydrolysis of ester bond and/or oxidation of unsaturated acyl 
chains of lipids as well as drug leakage from vesicles upon storage. Sterilization of liposomes 
is another issue because phospholipids are thermolabile and sensitive to sterilization 
procedures involving heat, radiation and/or chemical sterilizing agents. Filtration of 
liposomes using membrane (0.22 μm pore size) is the current sterilization method. This 
sterilization method is not suitable for liposomes larger than 0.2 μm and does not guarantee 
sterility from viruses [66]. To ensure treatment efficacy, therapeutic dose of the drug has to 
be delivered. Low encapsulation efficiency of liposomes for some drugs limits their 
usefulness clinically since high dose of lipids may be toxic. 
 
1.2.3.2. Polymeric micelles 
Polymeric micelles, self-assemblies of amphiphilic block copolymers, are currently 
recognized as one of the most promising formulations of anti-tumor drug deliveries, and 
several formulations have been intensively studied in clinical trials [28, 67-69]. The 
formation of polymeric micelles is governed by an intermolecular association force including 
hydrophobic/hydrophilic interactions, electrostatic interactions of charged groups and metal-
complex formation (Figure 1-3) [70-72].  
Polymeric micelles have a characteristic core-shell structure with a sub-100 nm size. 
They are composed of hydrophobic segments as internal core and hydrophilic segments as 
surrounding corona in aqueous medium. The hydrophobic core serves as a loading space for 
water-insoluble drugs, whereas the modification of hydrophilic shell affects pharmacokinetics 
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and biodistribution of drugs [28-37, 73-75]. The outer shell is usually made up of PEG which 
is hydrophilic and forms a hydration shell over the micelles. The hydration shell minimizes 
the interactions with the surrounding biocomponents such as cells and proteins, and therefore, 
demonstrates longevity in the bloodstream and effective tumor accumulation via the EPR 
effect [76, 77]. In summary, polymeric micelles possess several advantages such as nanoscale 
size (10 – 100 nm), high biocompatibility, high water solubility and prolonged blood 
circulation [40, 69, 78].  
Polymeric micelles are especially useful for the delivery of protein drugs, which offer 
an edge over a commonly used PEGylation technology. PEGylation is the covalent 
attachment of PEG moieties to a therapeutic agent with the aim of enhancing the 
pharmaceutical property of proteins [63]. However, it has a major drawback which is activity 
loss of the parent drug due to the chemical modification. This problem is non-existent for 
polymer micelle delivery of protein drug whereby encapsulation of protein drug is purely 
physical and no chemical modification of the parent drug is required. This would maintain 
the structure of the protein and hence its activity. 
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Figure 1-3 Polymeric micelles as intelligent nanocarriers for drug and gene delivery. 
Figure reproduced with permission from [70]. Copyright (2006) Elsevier. 
 
1.2.3.3. Nanoparticles albumin-bound (nab) technology 
Albumin is a family of globular proteins commonly found in blood plasma. 
Nanoparticle albumin-bound (nab) technology is a nanoparticle drug delivery platform that 
utilizes albumin receptor (gp60)-mediated transcytosis through microvessel endothelial cells 
in angiogenic tumor vasculature and targets the albumin-binding protein SPARC (Secreted 
Protein, Acidic and Rich in Cysteine), which is overexpressed in a majority of tumors [79]. 
Abraxane (nab-paclitaxel) is the first FDA approved nanotechnology based chemotherapeutic 
that has shown significant benefit in the treatment of metastatic breast cancer in randomized 
clinical studies versus Taxol and Taxotere. The nab-technology eliminates the need to use 
toxic solvents and surfactants including Cremophor and Tween to dissolve hydrophobic 
drugs. Several nab drugs are currently under development, including ABI-008 (nab-docetaxel) 
and ABI-009 (nab-rapamycin). In summary, nab-technology provides significant clinical 
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benefits through improved drug delivery and tumor targeting, and provides a broad platform 
for targeted drug delivery. 
 
1.2.3.4. Dendrimers 
Dendrimers are polymeric complexes that comprise a series of well-defined branches 
around an inner core with sizes (1 to 10 nm) and physiochemical properties similar to 
macromolecules [80, 81]. Despite their large molecular weight (1000 to 800,000 kDa), 
dendrimers are structurally well-defined with low polydispersity as compared to linear 
polymers [82]. The branching of dendrimers leads to semiglobular to globular structures and 
a high density of functionalities on the surface of the dendrimers. Functionalizing groups can 
be carbohydrates, peptides or silicon. One of the most commonly used and characterized 
dendrimers was polyamidoamines (PAMAMs) as gene carriers [83] 
One of the advantages of dendrimers is their ease of modification and conjugation to 
therapeutics. Drugs can also be loaded into dendrimers via hydrophobic interactions, 
hydrogen bondings, or chemical linkages. Dendrimers can be toxic and immunogenic. For 
instance, amino-terminated PAMAM dendrimers are toxic to cells and cause cell lysis due to 
their cationic surface charge. The amino-terminated PAMAM dendrimers are also found to 
be immunogenic [84]. The cytotoxicity and immunogenicity can be reduced with surface 
modification with chemically inert PEG. PEG chains increase the hydration of the dendrimer 
surface, reduce its overall positive charge and minimize its interaction with surrounding cells 
[80].  
 
1.2.3.5. Metal nanoparticles 
Metallic nanoshells, generally composed of inert metals such as gold or titanium, have 
been used for controlled release of chemotherapy [85]. Although these metal particles are 
Chapter 1: Introduction 
 
 18 
 
inert and biocompatible, a significant fraction of the particles is retained in the body after 
administration. The accumulation of metal particles after repeated administration can lead to 
toxicity. Therefore, most of the work on metal nanoparticle drug delivery has been in the 
preclinical stage [44]. 
 
1.2.4. Rational design of nanocarriers for cancer therapy 
Understanding the challenges in the delivery of nanocarriers is fundamental in 
formulating design strategies of the therapeutic carriers. There are two major obstacles for 
successful delivery of drug: premature degradation and limited transport across biological 
barriers (Figure 1-4) [86, 87]. These problems are particularly important for the delivery of 
biomolecules like peptides, proteins, and genes, for which they represent the limiting steps 
for their adequate clinical exploitation. Many water-soluble proteins undergo rapid 
breakdown because of environmental factors such as ionic strength, pH, or inactivation by 
enzymes present in the organism [88]. In this case, nanocarriers can protect the biomolecules 
from premature degradation and prevent the interaction with the biological environment 
prematurely. Nanocarriers are also able to facilitate their transport across the biological 
barriers and enhance absorption of the drugs into a selected tissue such as solid tumor. These 
will be translated to improved pharmacokinetic and drug distribution prolife [50]. 
For rapid and effective clinical translation, nanocarriers should meet several 
requirements. Firstly, the nanocarriers should be made of a material that is biocompatible, 
well characterized, and easily functionalized. Secondly, they should exhibit high differential 
uptake efficiency in the target cells over normal cells (or tissue). Thirdly, they should be 
either soluble or colloidal under aqueous conditions for increased effectiveness. Lastly, they 
should have an extended circulating half-life, a low rate of aggregation, and a long shelf life 
[50]. 
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Figure 1-4 Illustration of the different types of barriers drug molecules and drug 
delivery systems have to overcome before reaching the biological target into the body. 
The gray triangle gives a schematic representation of the drug loss while progressing across 
the different barriers toward the target site. Figure reproduced with permission from [87]. 
Copyright (2006) Springer. 
 
1.3. Green tea catechins 
1.3.1. Introduction 
Tea is a popular beverage consumed worldwide, especially in China and Japan. There 
are three major commercially available tea: green, black and Oolong tea. These three types of 
tea are harvested from the same plant called Camellia sinensis. The preparation method 
determines the type of tea produced. Green tea is non-fermented tea; black tea is fully 
fermented tea; and Oolong tea is partially fermented. Fermentation is an enzyme-mediated 
oxidation process whereby the catechins in the tea are oxidized and partially polymerized. 
One of the characteristics of green tea is the presence of large quantity of non-oxidized 
polyphenol compounds known as catechins [89]. 
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Catechins are flavanoid compounds found in green tea, which account for 30-40% of 
the dry weight of leaves. The major polyphenol catechins include epicatechin (EC), 
epigallocatechin (EGC), epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) 
(Figure 1-5). EGCG is the major polyphenolic constituent found in green tea which accounts 
for approximately 65% of the total catechin content [90]. The other polyphenolic compounds 
are found in lower abundance in green tea.  
 
 
Figure 1-5 Structures of the four major catechins in green tea. Figure reproduced with 
permission from [91]. Copyright (2001) Annual Reviews. 
 
1.3.2. Chemical and biochemical properties of green tea catechins 
Tea polyphenols or catechins are known to be strong antioxidants due to their 
polyphenolic structure [92]. Catechins are strong metal chelators, for example, the chelation 
of free Fe
3+
 ions prevents the formation of reactive oxygen species (ROS). They can also trap 
reactive species such as superoxide radical, singlet oxygen, hydroxyl ROS, nitric oxide, 
nitrogen dioxide, and peroxynitrite [93]. The vicinal dihydroxy or trihydroxy structures 
contribute to these antioxidative activities of tea polyphenols, but they also make these 
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compounds susceptible to air oxidation under alkaline or even neutral pH. In the case of 
EGCG, the autooxidation leads to the generation of superoxide anion and H2O2 and the 
formation of dimers such as theasinensins (Figure 1-6) [93, 94]. 
 
 
Figure 1-6 Proposed mechanism for the autooxidation of EGCG. Under neutral or 
slightly alkaline pH, EGCG is oxidized by molecular oxygen to form superoxide radical (•O2
−
) 
and EGCG radical (•EGCG) in a reaction probably catalyzed by trace metal ions such as Cu2+ 
and Fe
3+. The •O2
−
 can then react with another EGCG molecule to form •EGCG. •EGCG may 
collide with another •EGCG to form an EGCG dimer. More likely, •EGCG may react with 
EGCG to form EGCG dimer radical, which has the potential to react with molecular oxygen 
to generate EGCG dimer and •O2
−. An alternative mechanism is that the •EGCG is oxidized 
by molecular oxygen to form •O2
–
 and EGCG quinone, and the quinone would react with 
another molecule of EGCG to form the dimer. In either case, the •O2
−
 can react with another 
EGCG molecule to propagate the chain reaction. Addition of superoxide dismutase (SOD) to 
the culture medium enhances the conversion of •O2
−
 to H2O2 and thus inhibits the 
autooxidation of EGCG. Figure reproduced with permission from [93]. Copyright (2007) 
Elsevier. 
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Tea polyphenols are also known to interact with and precipitate proteins and nucleic 
acids. Hydrophobic interaction is considered to be the main interaction mode, which is then 
further stabilized by hydrogen bonding [95]. In the case of salivary proline-rich proteins 
(PRPs), hydrophobic stacking of phenolic rings against proline rings would constitute the 
primary associative driving force, followed by the formation of hydrogen bonds between 
phenolic hydroxy groups and carbonyl groups linked to proline amino groups, hence stitching 
up the resulting complex [96]. For example, EGCG has been shown to bind strongly to 67-
kDa laminin receptor [97], Bcl-2 proteins [98], and vimentin [99], and these proteins have 
been also proposed to be the target of EGCG for its anti-cancer activities [100]. 
 
1.3.3. Anticancer property of EGCG 
Studies of green tea catechins in animal, human, and in vitro models have shown that 
they possess antioxidant, anti-inflammatory, anti-allergy, and anti-viral properties [101]. A 
vast body of scientific research suggests that EGCG is responsible for the majority of the 
potential health benefits attributed to green tea consumption.  
The overwhelming majority of in vitro studies found that EGCG inhibits a vast array 
of biomedical relevant molecular targets and disease-related cellular processes at relatively 
high concentrations [96, 102-106]. EGCG has also been shown to possess cancer 
chemopreventive effects with potential anticancer activity, including apoptosis and growth 
arrest induction as well as angiogenesis inhibition in cancer cells through regulations of 
multiple signaling pathways [5, 107-109]. High potency of EGCG in cancer chemopreventive 
is thought to be due to its pyrogallol (B ring) and galloyl (D ring) moieties [91]. Studies of 
tumor suppression in animal models have resulted in lower tumor growth rates of many types 
of cancers including breast, lung, esophagus, and prostate cancers with EGCG [89, 110], 
although human epidemiological studies have been inconclusive [89].  
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1.4. Hypothesis and Aims 
After reviewing the current status and various treatment methods for cancer, the 
benefit of using nanotechnology in devising drug carriers for cancer therapy is apparent. 
Many macromolecular drug carriers have been significantly improved to alter the 
pharmacokinetics and biodistribution of drugs [28-37], wherein the carrier is just an excipient 
to deliver and the therapeutically relevant compound is only the drug. We were inspired to 
design an improved delivery system enabling synergistic therapeutic effects by the carrier as 
well as the drug, by utilizing the binding property of EGCG to various biological molecules 
[110, 111]. Even though many studies have discussed the beneficial bioactivities of EGCG, 
our work is the first to utilize EGCG as a carrier of biological molecules aiming at synergistic 
effects due to the carrier itself. This approach will provide unique angle in designing 
biomaterials that possess versatile bioactivities originating from green tea. 
In the previous section, we have discussed about the potential therapeutic efficacy of 
EGCG including antioxidant, anti-inflammatory, anti-allergy, and anti-viral, anti-
angiogenesis and anticancer [5, 101, 108]. It is widely known that EGCG is capable of 
association with peptides and proteins forming soluble or precipitable complexes mainly by 
hydrophobic interaction and hydrogen bonding [112]. These complexes affect a variety of 
enzyme activities and signal transduction pathways at micromolar or nanomolar levels [113]. 
These interactions open up the possibility of delivering therapeutic proteins using EGCG by 
utilizing the binding property of EGCG with various biological molecules [110, 111]. 
This project aims to develop a protein delivery system utilizing the green tea 
catechins to deliver therapeutic protein to site of interest, particularly to deliver an anticancer 
monoclonal antibody, Herceptin (trastuzumab), to the tumor site. Herceptin (trastuzumab) is 
an FDA approved humanized monoclonal antibody against the HER2/neu (erbB2) receptor 
and induces regression of HER2-overexpressing metastatic breast cancer tumors. 
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Overexpression of human epidermal growth factor receptors type 2 (HER2) occurs in 20 to 
30% of invasive breast carcinoma. HER2 signaling promotes cell proliferation through the 
RAS–MAPK pathway and inhibits cell death through the phosphatidylinositol 3'-kinase–
AKT (PI3K/Akt) pathway [114, 115]. Herceptin might decrease signaling by prevention of 
HER2 receptor dimerization, increased endocytotic destruction of the receptor, inhibition of 
shedding of the extracellular domain, and immune activation [114, 116, 117]. Studies in an 
animal model of breast cancer in which HER2 is overexpressed indicated that angiogenesis 
may be inhibited by Herceptin, which induces normalization and regression of the 
vasculature by modulating pro-angiogenic and anti-angiogenic factors [117, 118]. 
Recently, our laboratory has designed and synthesized two EGCG-derivative 
compounds: oligomerized EGCG (OEGCG) and poly(ethylene glycol)-EGCG conjugate 
(PEG-EGCG). The specific objective of this project is to design and develop a self-assembled 
core-shell micellar nanocomplex (MNC) comprising of OEGCG, PEG-EGCG and a 
therapeutic protein (e.g. Herceptin (trastuzumab)) for the treatment of HER2-overexpressing 
cancer.  
 
1.5. Structure of dissertation 
This dissertation is divided into six chapters. An overview of the contents of each 
chapter is provided here. The thesis is a detailed and sequential document, with each chapter 
building on the conclusions of the previous chapter. Firstly, Chapter 1 introduces the 
background on cancer therapy and nanotechnology in drug delivery and focuses on polymeric 
micelles for the delivery of cancer therapeutics.  
Chapter 2 provides details of the synthesis of the two EGCG derivatives, namely 
oligomerized EGCG (OEGCG) and poly(ethylene glycol)-EGCG conjugate (PEG-EGCG), 
and discusses the interaction between EGCG derivatives and proteins, including the factors 
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that affect these interactions. Chapter 3 provides details on our design of Herceptin micellar 
nanocomplex (Herceptin-MNC) comprising of Herceptin, OEGCG and PEG-EGCG and 
describes the methodologies in characterizing the micellar system. Chapter 4 investigates the 
efficacy of Herceptin-MNC in inhibiting cancer cell growth and demonstrates the synergism 
between EGCG derivatives and Herceptin on various cancer cell lines in vitro. This chapter 
also elucidates the mechanisms governing Herceptin-MNC anticancer efficacy. Chapter 5 
assesses tumor regression efficacy of Herceptin-MNC on BT-474 breast cancer in vivo and 
explores its biodistribution and pharmacokinetics. Chapter 6 summarizes and concludes the 
newly developed MNC system in improving the delivery of therapeutic proteins and suggests 
areas for further research and work. 
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Chapter 2 – Synthesis of EGCG Derivatives and Their 
Interactions with Proteins 
 
2.1. Introduction 
Phenolic-protein interactions have been a topic that has drawn continuous research 
due to their importance in food [119]. It is widely known that polyphenols including (–)-
epigallocatechin-3-O-gallate (EGCG) are capable of association with peptides and proteins 
forming soluble or precipitable complexes mainly by hydrophobic interaction and hydrogen 
bonding [120-122]. Polyphenols interact with salivary proline-rich proteins and cause the 
astringency sensation [121, 123]. 
In recent years, EGCG, a major ingredient of green tea, has attracted considerable 
attention because it has been recognised to have biochemical and pharmacological effects 
including antioxidant, anticarcinogenic, antimutagenic, antiviral, antibiotic and anti-
inflammatory properties, which were demonstrated in numerous human, animal and in vitro 
studies [2, 5, 124]. Although many studies have confirmed the beneficial bioactivities of 
polyphenols (including EGCG) or their binding property to proteins, there has been no report 
on using the polyphenol/protein complexes for delivering proteins. Our laboratory is driven 
to design a novel protein delivery system by utilizing the binding property of EGCG to 
various proteins in achieving synergistic therapeutic effects contributed by both the 
therapeutic protein and the EGCG-derived carrier. To achieve this objective, EGCG 
derivatives would be synthesized and studied for their interactions with proteins. 
In this chapter, the synthesis and characterization of two EGCG derivatives, 
oligomerized EGCG (OEGCG) and poly(ethylene glycol)-EGCG conjugate (PEG-EGCG), 
are described. OEGCG was then complexed with Herceptin (trastuzumab) or bovine serum 
albumin (BSA), and their interactions studied by monitoring the complex size change when 
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OEGCG was added to the proteins or when surfactant was added to the protein/OEGCG 
complexes. Herceptin is an FDA-approved humanized monoclonal antibody targeted against 
the extracellular domain of HER2 for the treatment of invasive breast cancers that 
overexpress HER2 [125]. Numerous studies have been performed on factors affecting 
polyphenol-protein interactions, such as pH, temperature, protein size, and amino acid 
composition [126-128]. Based on these studies, we investigated how these factors affected 
the interaction between OEGCG and proteins. Conformational changes due to the 
complexation would also be discussed. The feasibility of the formation of core-shell micellar 
nanocomplexes (MNC) delivery system utilizing protein/OEGCG complexes and PEG-
EGCG were tested. 
 
2.2. Materials and methods 
2.2.1. Synthesis of OEGCG and PEG-EGCG 
To synthesize OEGCG, EGCG (Kurita Ltd., Japan) (1 g) was dissolved in a solvent 
mixture containing 11.6 ml of acetic acid, 9.2 ml of dimethyl sulfoxide (DMSO) and 41.6 ml 
of water. The reaction was initiated with the addition of acetaldehyde (7.2 ml), and was 
conducted at room temperature (pH 2) under a nitrogen atmosphere for 72 h. The resulting 
products were dialyzed (molecular weight cut-off (MWCO) = 2000) against methanol to 
remove any unreacted EGCG, followed by dialysis against water to remove methanol. The 
purified products were lyophilized to give OEGCG. 
To synthesize PEG-EGCG, the aldehyde-terminated PEG (PEG-CHO, Mw 5000, 
NOF Co., Japan) (0.35 g) and EGCG (0.65 g) were separately dissolved in a solvent mixture 
of 2.1 ml of acetic acid, 2.7 ml of DMSO and 7.5 ml of water. The reaction was initiated with 
the dropwise addition of the PEG-CHO solution to EGCG solution, and was conducted at 
room temperature (pH 2) under a nitrogen atmosphere for 72 h. The resulting products were 
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dialyzed (MWCO = 3500) against a gradient of solvent mixture (i.e. with DMSO gradually 
replaced by water), and lyophilized to give PEG-EGCG. 
 
2.2.2. Preparation of protein/OEGCG complexes 
OEGCG was dissolved in DMSO while Herceptin and BSA were dissolved in 
Phosphate Buffered Saline (PBS, pH 7.4) or deionized water. To prepare protein/OEGCG 
complexes (i.e. Herceptin/OEGCG or BSA/OEGCG complexes), OEGCG was added to the 
0.2 μm filtered protein solutions (Herceptin or BSA) and mixed well by pipetting. 
 
2.2.3. Protein/OEGCG association and dissociation 
The protein/OEGCG complexes were formed according to method in section 2.2.2. 
To study the effect of OEGCG concentration on the complex formation, OEGCG (3 – 428 
µg/ml) was complexed with protein at constant concentration (Herceptin = 0.5 mg/ml, BSA = 
0.5 mg/ml). The effect of protein concentration in the complexation was studied by the 
addition of OEGCG (24 µg/ml) to protein at various concentrations (0.01 – 5 mg/ml).  
To further study the interaction between protein and OEGCG, Herceptin/OEGCG 
(Herceptin = 0.5 mg/ml, OEGCG = 24 µg/ml) and BSA/OEGCG (BSA = 0.5 mg/ml, 
OEGCG = 24 µg/ml) complexes were dissociated with Triton X-100. The size and 
polydispersity of samples were evaluated by Dynamic Light Scattering (DLS) with a particle 
sizer (Brookhaven Instruments Co.). 
 
2.2.4. Factors affecting protein/OEGCG complexation 
Herceptin/OEGCG (Herceptin = 0.5 mg/ml, OEGCG = 24 µg/ml) and BSA/OEGCG 
(BSA = 0.5 mg/ml, OEGCG = 24 µg/ml) complexes were formed at various temperatures 
(17, 25, 37, 45, and 55 °C), pH (2 – 10) and ionic strengths (0.01 – 5 M NaCl). The effect of 
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temperature was monitored using a particle sizer with a temperature-controlled sample 
compartment. The effect of pH in the formation of protein/OEGCG complex was examined 
by preparing the complex in 0.01 M of phosphate buffer (pH 2 – 10). Phosphate buffers of 
different pH were prepared by mixing 0.01 M of phosphoric acid and 0.01 M of trisodium 
phosphate in proportions to produce a buffer of a desired pH. This protocol was adopted from 
Naczk‟s research paper [128]. Ionic strength was adjusted by adding appropriate amount of 
NaCl to 0.01 M of phosphate buffer. The size and polydispersity of samples were evaluated 
by DLS. 
 
2.2.5. Surface charge of protein/OEGCG complexes 
Herceptin/OEGCG (Herceptin = 0.5 mg/ml, OEGCG = 24 µg/ml) and BSA/OEGCG 
(BSA = 0.5 mg/ml, OEGCG = 24 µg/ml) complexes were formed in deionized water and 
measured for their zeta potential using a zeta potential analyzer (Zetapals). 
 
2.2.6. Circular dichroism (CD) spectroscopy 
Herceptin/OEGCG (Herceptin = 0.5 mg/ml, OEGCG = 2.4 µg/ml) and BSA/OEGCG 
(BSA = 0.5 mg/ml, OEGCG = 24 µg/ml) complexes were prepared in PBS. The CD spectra 
of the complexes were recorded at room temperature with a CD spectropolarimeter (JASCO, 
J-810) using a quartz cell having a path length of 1.0 mm. The spectra were obtained at a 
scanning speed of 10 nm/min in for 197–260 nm with solvent subtracted. They were 
averaged from 3 runs of each sample. The acquired CD spectra were then converted to mean 
residue ellipticity by using the following equation: 
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where θM is residue ellipticity [deg.M
−1
.m
−1
], θobs is the observed ellipticity corrected for the 
buffer at a given wavelength [mdeg], MRW is residue molecular weight (Mw/number amino 
acids), c is peptide concentration [mg/ml], and l is the path length [cm]. 
 
2.2.7. Formation of core-shell micellar nanocomplex (MNC) 
MNC were formed by the addition of PEG-EGCG (which was dissolved in DMSO) to 
the pre-formed protein/OEGCG core complexes. PEG-EGCG of different concentrations was 
added to the Herceptin/OEGCG complexes (Herceptin = 0.5 mg/ml, OEGCG = 0.285 ng/ml 
and 12 μg/ml) or BSA/OEGCG complexes (BSA = 0.5 mg/ml, OEGCG = 24 and 195 μg/ml). 
The resulting MNCs were characterized in size by DLS. 
 
2.3. Results and discussion 
2.3.1. Synthesis of OEGCG and PEG-EGCG 
OEGCG and PEG-EGCG were synthesized by Baeyer reaction between an aldehyde 
group and a nucleophilic A ring of EGCG. OEGCG was synthesized by the coupling of 
EGCGs through an ethyl (CH3-CH) bridge in the presence of acetaldehyde (Figure 2-1a). 
Studies have shown that the condensation of (+)-catechin or (–)-epicatechin in the presence 
of acetaldehyde gave the condensed A rings of catechins through the CH3-CH bridges linked 
at C6-C6, C8-C8 and C6-C8 (R and S) bonds [129]. 
1
H and 
13
C nuclear magnetic resonance 
(NMR) analysis of the product proved the condensation of EGCG linked through a CH3-CH 
bridge at the C6 and C8 positions of the A ring (see Appendix A). Mass spectrometry 
detected the presence of hexamer with a series of peaks separated by the regular incremental 
mass of an EGCG unit linked by the CH3-CH bridge (m/z = 485 of EGCG-CHCH3 fragment 
and m/z = 511 of CH3CH-EGCG-CHCH3 fragment) (see Appendix B). 
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PEG-EGCG was synthesized by conjugation between a terminal aldehyde group of 
PEG-CHO and the A ring of EGCG using the same reaction as for OEGCG synthesis (Figure 
2-1b). The linkage between PEG and EGCG was detected by 
13
C NMR analysis (see 
Appendix C). The mass spectrum demonstrated that the product had two molecules of EGCG 
bound to an end of PEG chain (see Appendix D). 
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Figure 2-1 Synthesis of a, OEGCG and b, PEG-EGCG. 
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2.3.2. OEGCG and proteins interaction studies 
EGCG are known to interact with peptides and proteins forming soluble or 
precipitable complexes mainly by hydrophobic interaction and hydrogen bonding [120-122]. 
Polyphenols interact with salivary proline-rich proteins and result in complexation and 
precipitation [123]. In this study, we investigated the interaction of the newly synthesized 
OEGCG with proteins, including BSA and Herceptin. 
To study the mode of interaction between protein and OEGCG, Herceptin and BSA 
were first complexed with OEGCG and monitored for their size changes. In the 
protein/OEGCG complexation study, protein concentration was first kept constant while 
OEGCG concentrations were varied. In Figure 2-2a, both Herceptin and BSA were shown to 
be ~ 9 nm in hydrodynamic diameter (HD) prior to complexation. The size increased with the 
addition of OEGCG to Herceptin, indicating the formation of Herceptin/OEGCG complex. 
The complex size increased with increasing OEGCG concentration. The same phenomenon 
was observed when OEGCG was added to BSA. Herceptin and OEGCG were shown to form 
larger complex as compared to BSA and OEGCG within the range of concentration tested, 
indicating a stronger interaction between Herceptin and OEGCG. The results were in good 
agreement with the study performed by Naczk et al., which showed linear relationship 
between the amount of tannin-protein complex formed and the amount of tannin added to the 
reaction mixture [128]. 
When the concentration of OEGCG was kept constant and protein concentration was 
varied, the size of the complex increased up to a maximum point, followed by a decrease with 
further increase in protein concentration (Figure 2-2b). These observations suggested 
OEGCG interacted with proteins via non-covalent bonding.  
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Figure 2-2 Protein/OEGCG complexes formation. a, Size of Herceptin/OEGCG 
complexes (white circles) and BSA/OEGCG complexes (white squares) formed with 0.5 
mg/ml of Herceptin and BSA, respectively. b, Size of Herceptin/OEGCG complexes (white 
circles) and BSA/OEGCG complexes (white squares) formed with 0.024 mg/ml of OEGCG. 
The results are reported as mean values, and the error bars represent standard deviation (s.d.) 
(n = 3). 
 
Various proposals have been made on the mode of interaction between polyphenols 
and proteins and the principal suggestions are that the two species reversibly complex via 
hydrogen bonding and hydrophobic interactions [127, 130]. Hoff et al. have suggested that 
hydrophobic interaction may dominate the complexation since the establishment of hydrogen 
bonds of the solutes in aqueous media was not thermodynamically favorable [130]. When 
different concentrations of Triton X-100 were added to the pre-formed Herceptin/OEGCG 
and BSA/OEGCG complexes, the complex size decreased with increasing amount of Triton 
X-100 added, indicating dissociation of the complexes (Figure 2-3). This observation 
supported the proposition by Hoff et al. whereby both Herceptin/OEGCG and BSA/OEGCG 
were dissociated by Triton X-100 due to hydrophobic competition (Figure 2-3). Since both 
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proteins and OEGCG contain hydrophobic regions (i.e. the aromatic nuclei of OEGCG and 
the aliphatic and aromatic side chains of the protein amino acids), these regions are likely to 
participate in the interaction [130]. 
 
 
Figure 2-3 Protein/OEGCG complex size change with addition of Triton X-100. 
Dissociation of Herceptin/OEGCG complexes (white circles) and BSA/OEGCG complexes 
(white squares) by Triton X-100. The results are reported as mean values, and the error bars 
represent s.d. (n = 3). 
 
Herceptin/OEGCG formed larger complexes and required higher amount of Triton X-
100 to be dissociated than BSA/OEGCG. This observation implied that Herceptin interacted 
strongly with OEGCG, which could be due to its relatively higher proline content, aromatic 
rings and molecular weight (Table 2-1). 
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Table 2-1 Herceptin and BSA protein profile. Data reproduced with permission from [131]. 
Copyright (2011) Oxford University Press. 
 Herceptin BSA 
Molecular weight 145,532 g/mol 66,463 g/ml 
Isoelectric point at 25 °C 8.45 4.7 
No. of amino acid residues 1,328 585 
Amino acid composition Ala 141 Cys 57 Asp 105 
Glu 105 Phe 81 Gly 166 
His 44 Ile 56 Lys 158 
Leu 174 Met 18 Asn 89 
Pro 166 Gln 115 Arg 75 
Ser 303 Thr 203 Val 217 
Trp 40      Tyr 115 
Ala 48 Cys 35 Asp 41 
Glu 58 Phe 30 Gly 17 
His 16 Ile 15 Lys 60 
Leu 65 Met 5 Asn 14 
Pro 28 Gln 21 Arg 26 
Ser 32 Thr 34 Val 38 
Trp 3        Tyr 21 
   
 Aromatic rings 
Phe 6%             His 3.3% 
Trp 3%           Tyr 8.66% 
Aromatic rings 
Phe 5.13%        His 2.7% 
Trp 0.51%        Tyr 3.6% 
   
 Proline 
Pro 12.5% 
Proline 
Pro 4.8% 
 
 
2.3.3. Factors affecting the protein/OEGCG complexation 
2.3.3.1. Temperature 
Various reports have shown that precipitation of tannins with proteins increases with 
temperature as a result of an increase in hydrophobic interactions [122, 130]. Unexpectedly, 
our experimental results showed a different trend, whereby the size of the complex decreased 
with increasing temperature from 17 to 37 °C (Figure 2-4a). To further study this 
phenomenon, Herceptin/OEGCG complexes were observed with transmission electron 
microscope (TEM), which showed a mixture of Herceptin/OEGCG complex consisting of 
complex nuclei and secondary association of the nuclei (see Appendix E). We believed that 
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the complexes were formed as nuclei, which then secondarily associate to form larger 
aggregates bridged by OEGCG. Studies on the interaction of BSA and polyphenols suggest 
that polyphenols are multivalent ligands, and may form crosslinks between two or more 
protein molecules [132, 133]. Complex size reduction was the result of the dissociation of the 
secondary association. A characteristic feature of hydrophobic interaction is that it increases 
with an increase in temperature, while the opposite is true for interactions based on hydrogen 
bonding [130]. This suggested that the dominant force that governed the secondary 
association of protein/OEGCG complex nuclei was hydrogen bonding. 
 
2.3.3.2. pH 
To study the effect of pH in complexation of OEGCG with protein, Herceptin and 
BSA were independently complexed with OEGCG at various pH ranging from 2 to 10. 
Figure 2-4b showed that Herceptin/OEGCG complex achieved its maximum size at pH 8 and 
BSA/OEGCG at pH 4. Naczk et al. have shown that the interaction of polyphenols with 
proteins is maximal at the proximity of the isoelectric points of the proteins [128]. Table 2-1 
showed that the isoelectric points of Herceptin and BSA were 8.45 and 4.7, respectively. 
When the protein/OEGCG complexes were formed at various pH, the complex size increased 
up to a maximum point near the protein isoelectric point, followed by an abrupt decrease. 
 
  
Chapter 2: Synthesis of EGCG derivatives and their interactions with proteins 
 
 39 
 
 
Figure 2-4 Factors affecting the complexation of protein/OEGCG: a, temperature, b, pH 
and c, ionic strength. Herceptin/OEGCG (white circles) and BSA/OEGCG (white squares). 
The results are reported as mean values and the error bars represent s.d. (n = 3). 
 
2.3.3.3. Ionic strength 
The influence of ionic strength on protein/OEGCG complexation was studied by 
monitoring the size of the complex when formed in a buffer of different ionic strengths. The 
ionic strength of the buffer was adjusted by the addition of NaCl to 0.01 M phosphate buffer. 
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Figure 2-4c showed that the size of the protein/complex increased with increasing ionic 
strength. This was because hydrophobic interactions increase with ionic strength [130]. 
Generally, proteins have high solubility at a low ionic strength and a low solubility at a high 
ionic strength [134]. This is the principle of the salting-out technique for protein purification. 
In aqueous solution, hydrophobic amino acids are folded away from the water molecules, 
leaving the hydrophilic amino acids to interact with the water molecules. When the salt 
concentration is increased, some of the water molecules are attracted by the salt ions from the 
protein surface, exposing more hydrophobic portions to interact with each other and form 
large protein aggregates.  
 
2.3.4. Changes to protein conformation upon complexation 
The activity of a protein is largely influenced by its conformation. Binding of 
polyphenols to protein might alter the conformation, and affect the activity of the protein. To 
study if OEGCG altered the conformation of the protein, the secondary structure of Herceptin 
and BSA was analyzed by CD spectroscopy before and after complexation. The 
protein/OEGCG complexes were then dissociated with 0.1 % Triton X-100, and analyzed for 
their secondary structure. Herceptin maintained its secondary structure after complexation 
with OEGCG (Figure 2-5a). In addition, when Herceptin was dissociated from OEGCG, its 
structure remained unchanged. Likewise, OEGCG did not alter the conformation of BSA 
upon complexation and dissociation (Figure 2-5b). This observation supported the idea of 
using OEGCG as the carrier for therapeutic protein by complexation, since the conformation 
of the protein was maintained and the protein activity would not be compromised. 
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Figure 2-5 CD spectra of protein/OEGCG complexes. a, CD spectra of Herceptin (0.5 
mg/ml) (white circles), Herceptin/OEGCG complex (Herceptin = 0.5 mg/ml, OEGCG = 2.4 
μg/ml) (white squares), and dissociated Herceptin/OEGCG complex (white triangles). b, CD 
spectra of BSA (0.5 mg/ml) (white circles), BSA/OEGCG complex (BSA = 0.5 mg/ml, 
OEGCG = 24 μg/ml) (white squares), and dissociated BSA/OEGCG complexes (white 
triangles). The spectra are representative of two independent experiments. 
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2.3.5. Formation of core shell micellar nanocomplex (MNC) as carrier for therapeutic 
proteins 
The ability of OEGCG to complex with protein and retain its activity is critical in OEGCG‟s 
application as a therapeutic carrier. Apart from protecting against loss in protein activity, the 
delivery system should prolong the protein circulation time in vivo. The introduction of 
poly(ethylene glycol) (PEG) to the delivery system has been shown to increase the circulation 
time in vivo by escaping the renal filtration due to the hydrated outer shell [39, 49, 63]. In our 
strategy, PEG was conjugated to EGCG monomer to formulate PEG-EGCG, which served as 
the shell for a protein/OEGCG core in a core-shell MNC. 
Figure 2-6 showed the formation of core-shell MNC by using core complexes of 
different sizes and different proteins. Because the interactions between OEGCG and proteins 
were different for Herceptin/OEGCG and BSA/OEGCG complexes, the size of the core 
complexes was also varied. PEG-EGCG of different concentration was added to the 
Herceptin/OEGCG or BSA/OEGCG core complexes. When sufficient PEG-EGCG was 
added to the core complex, stable MNC was formed whereby no size change was observed 
with further addition of PEG-EGCG. As such, the MNC offers the possibility of utilizing 
EGCG derivatives as the carrier for therapeutic proteins. 
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Figure 2-6 Core-shell MNC formation. Complex size obtained when PEG-EGCG of 
various concentrations was added to the pre-formed BSA/OEGCG complexes with 24 µg/ml 
(white circles) and 195 µg/ml (white squares) of OEGCG. Complex sizes obtained when 
PEG-EGCG of various concentrations was added to the pre-formed Herceptin/OEGCG 
complexes with 0.285 ng/ml (black circles) and 12 µg/ml (black squares) of OEGCG. The 
points represent mean values, and the error bars represent s. d. (n = 3). 
 
2.4. Summary 
OEGCG and PEG-EGCG were successfully synthesized and characterized by 
1
H 
NMR, 
13
C NMR, matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) and electrospray ionization time-of-flight mass spectrometry (ESI-TOF 
MS). Both Herceptin and BSA were shown to complex with OEGCG by mainly hydrophobic 
interactions. Due to the different amino acid compositions and molecular weights of 
Herceptin and BSA, the sizes of complexes formed were different. Herceptin was shown to 
form larger complex with OEGCG due to its high aromatic rings, proline content and 
molecular weight as compared to BSA. The complexation was shown to be affected by 
temperature, pH and ionic strength. Protein/OEGCG complex size generally decreased with 
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increasing temperature. Complex size gradually increased with pH, and reached its maximum 
point at the proximity of the protein isoelectric point followed by a drastic decrease. The size 
of the complex increased with increasing ionic strength.  
The conformation of the protein was not altered by protein complexation with 
OEGCG, suggesting no activity loss and the suitability of EGCG-based carrier for the 
delivery of therapeutic proteins. A new protein carrier was formulated as a core-shell MNC 
by the addition PEG-EGCG to the protein/OEGCG complex. In the following three chapters 
presented our effort to develop the EGCG-derived MNCs for delivering therapeutic proteins 
for the treatment of breast cancer. 
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Chapter 3 – Design of Self-assembled Micellar Nanocomplexes 
Comprising of Green Tea Catechins and Herceptin 
 
3.1. Introduction 
Based on the findings in the previous chapter, we are motivated to design an 
improved delivery system whereby the carrier would display therapeutic effects. This was 
achieved by utilizing the binding property of epigallocatechin gallate (EGCG) with various 
biological molecules including proteins [110, 111]. EGCG has been recognized to possess 
various therapeutic efficacies including anticancer effects [2-9]. Although many studies have 
discussed the beneficial bioactivities of EGCG, this work is the first to utilize EGCG as a 
carrier for biological molecules, aiming at combinational therapeutic effects between the 
carrier and the drug. 
Our micellar nanocomplex (MNC) carrier was comprised of two EGCG derivatives 
designed to bind with proteins in a spatially ordered structure. One of them was oligomerized 
EGCG (OEGCG), which was designed to stabilize the core by strengthening the binding 
property of EGCG with proteins [135]. The other derivative was poly(ethylene glycol)-
EGCG (PEG-EGCG), which was tailored to bind to the OEGCG/protein complex as an inert 
and hydrophilic shell with extended PEG chains. The MNC was formed through two 
sequential self-assemblies in an aqueous solution: (i) the complexation between OEGCG and 
proteins to form the core, and (ii) the complexation of PEG-EGCG surrounding the pre-
formed core to form the shell. 
With extended PEG chains as outer shell of the micellar system, the hydration shell 
would reduce protein immunogenicity and prevents rapid renal clearance and proteolysis of 
protein by reticuloendothelial system (RES) uptake, leading to longer circulation time in vivo 
[39, 49]. The tailored nanosize (< 100 nm) of the MNC coupled with long circulation time 
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would enable passive tumor targeting by the enhanced permeability and retention (EPR) 
effect [136, 137]. 
In this chapter, the design and characterizations of MNC comprised of Herceptin, 
OEGCG and PEG-EGCG is discussed. Since the MNC was formed by two-step self-
assemblies, the interaction between the components in each assembly step was studied 
mainly by the measurement of complex size using dynamic light scattering (DLS). The 
stability of the resultant MNC was also investigated as an important aspect of the delivery 
system. The protection rendered by our carrier system to the protein was also studied by 
subjecting the MNC to proteinase K. 
 
3.2. Materials and methods 
3.2.1. Preparation of micellar nanocomplexes (MNC) 
OEGCG and PEG-EGCG were dissolved in dimethyl sulfoxide (DMSO) while 
Herceptin and BSA (0.5 mg/ml) were dissolved in phosphate buffered saline (PBS) (pH 7.4). 
To prepare Herceptin or BSA micelles, OEGCG was added to the 0.2 μm filtered herceptin or 
BSA solution, respectively, to form the micellar core, followed by the addition of PEG-
EGCG to the preformed core to yield MNC.  
 
3.2.2. Particle size and morphology study 
The size and polydispersity of samples were evaluated by DLS with a particle sizer 
(Brookhaven Instruments Co.). The morphology of the samples was characterized with 
transmission electron microscope (TEM) (FEI Tecnai G
2
 F20 S-Twin, 200 kV). One hundred 
μl of MNC solution stained with 0.001 mg/ml phosphotungstic acid was fixed on a copper 
grid coated with carbon film, and dried at room temperature overnight. 
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3.2.3. Dissociation study of Herceptin/OEGCG core complex  
Herceptin/OEGCG complexes containing 0.5 mg/ml of Herceptin and 3 μg/ml of 
OEGCG were formed according to the method above. Different dissociating agents, 
including Tween 20, Triton X-100, sodium dodecyl sulfate (SDS), urea and NaCl were added 
to the complex to dissociate OEGCG from Herceptin. The size and polydispersity of the 
samples were evaluated by DLS. 
 
3.2.4. Activity of xanthine oxidase, α-amylase and lysozyme 
The activity of xanthine oxidase (from buttermilk, Wako Chemical) was measured by 
determining uric acid production (295 nm) with ultraviolet-visible (UV-Vis) 
spectrophotometry (Hitachi, Japan). The solution contained protein (50 μg/ml) and OEGCG 
(50 μg/ml) in a 0.1 M phosphate buffer with or without Triton X-100 (0.1%). Each 
measurement was run in triplicate. 
The activity of α-amylase (from Apergillus oryzae, Fluka) was assayed with an 
activity kit (Molecular Probes, E-11954) using a fluorescence spectrophotometer (Hitachi, 
Japan, ex = 505 nm and em = 512 nm). The solution contained protein (2.5 μg/ml) and 
OEGCG (2.5 μg/ml) in a 0.1 M phosphate buffer with or without Triton X-100 (0.1%). Each 
measurement was run in triplicate. 
The activity of lysozyme (from egg white, Sigma Chemical) was determined 
spectrophotometrically at 450 nm by the decrease in turbidity due to the cleavage of 
glucosidic linkages of micrococcus lysodeikticus using a UV-Vis spectrophotometer (Hitachi, 
Japan). The solution mixture contained protein (2.5 μg/ml) and OEGCG (2.5 μg/ml) with or 
without Triton X-100 (0.1%). To start the reaction, 0.25 mg/ml of micrococcus lysodeikticus 
was added to the solution. Each measurement was run in triplicate.  
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3.2.5. Herceptin/OEGCG/PEG-EGCG MNC formation 
Herceptin/OEGCG complexes containing 0.5 mg/ml of Herceptin and 0.1–12 μg/ml 
of OEGCG were formed according to the method in 3.2.1. Different concentrations of PEG-
EGCG were added to the pre-formed Herceptin/OEGCG complexes. The sizes of MNCs 
were characterized by DLS. 
The importance of composition and formation sequence of Herceptin-MNC was 
evaluated for the complexation of Herceptin with the compounds and the stability of the 
complexes. The complexes were formed with 0.5 mg/ml of Herceptin, 500 μg/ml of PEG, 
500 μg/ml of PEG-EGCG, and 12 μg/ml of OEGCG. The complex size was evaluated by 
DLS. 
 
3.2.6. Surface charges of the complexes at each assembly step 
The surface charge of the complexes at each assembly step was monitored using 
Zetasizer Nano (Malvern Instrument Ltd., Worcestershire, UK) with a folded disposable 
capillary cell. Particle size and zeta potential measurements were conducted thrice per 
sample, and reported as the mean ± standard deviation (n = 3). The compounds used in this 
study consisted of 0.5 mg/ml of Herceptin, 24 μg/ml of OEGCG, 2.87 mg/ml of PEG-EGCG, 
and 2.87 mg/ml of PEG. 
 
3.2.7. Herceptin-MNC stability assessment 
Herceptin-MNC were prepared with 0.5 mg/ml of Herceptin, 24 μg/ml of OEGCG, 
261 μg/ml of PEG-EGCG according to the method in 3.2.1 and incubated at 37°C. The MNC 
was monitored for its size over 15 days. In another experiment, Herceptin-MNC of similar 
composition was subjected to dilution with the addition of PBS. The size of the MNC was 
determined by DLS.  
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3.2.8. Synthesis of FITC-conjugated Herceptin 
Herceptin (10 mg, 68 nmol, Roche) and FITC (2.4 mg, 62 nmol, Sigma) were 
dissolved in borate buffer (0.1 M, pH 8.5) separately. FITC was added dropwise to the 
Herceptin solution with gentle stirring. The mixture was then incubated in the dark at room 
temperature for 17 h. The mixture was purified with Vivaspin 15R (MWCO = 10,000, 
Sartorius Stedim). FITC-conjugated Herceptin (Herceptin-FITC) was kept at 4°C in the 
refrigerator as stock solution. The conjugation degree was determined by fluorescence 
spectrophotometer (Hitachi, Japan, ex = 490 nm and em = 530 nm) for FITC and by BCA 
protein assay (Pierce, Thermo Scientific) for Herceptin. For quantification of FITC, a 
standard curve was generated by obtaining the fluorescence intensity for FITC concentrations 
of 0.4–100 µg/ml. 
 
3.2.9. Proteolysis 
Protein degradation was estimated by monitoring the fluorescence intensity of 
Herceptin-FITC conjugates, when the samples were subjected to proteinase K (0.05 mg/ml). 
Herceptin-MNC was prepared in PBS according to the method in section 3.2.1. A 
fluorescence spectrophotometer was employed for this study (Hitachi, Japan, ex = 490 nm 
and em = 530 nm). 
 
3.3. Results and discussion 
3.3.1. Structural design of MNC 
We designed the core-shell MNC comprised of two EGCG-derivative compounds 
binding to proteins in a spatially ordered structure. This led to the formation of a MNC 
through spontaneous self-assembly in an aqueous solution. The MNC was fabricated using 
two sequential self-assemblies: (i) the complexation between OEGCG and proteins to form 
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the core, and (ii) the complexation of PEG-EGCG surrounding the pre-formed core to form 
the shell (Figure 3-1a). OEGCG has been shown to have greater antioxidant activity, in terms 
of radical scavenging ability, and greater enzyme inhibition than monomeric EGCG on a per 
unit basis [135]. PEG in the PEG-EGCG was expected to improve plasma half-life of the 
protein. The resultant MNC displayed a PEG shell with a core of OEGCG/protein complex. 
By reducing protein immunogenicity and preventing rapid renal clearance and proteolysis of 
protein, this MNC could reduce the need for frequent injections or infusion therapy [28, 34]. 
Figure 3-1b and c show the transmission electron microscopy (TEM) images and the 
hydrodynamic diameters (HD‟s) of the complexes formed at each step of the sequential self-
assemblies. Herceptin (trastuzumab) showed a HD of ~ 9 nm. Adding OEGCG to the 
Herceptin solution led to the spontaneous formation of a complex with a relatively broad size 
distribution up to ~ 800 nm in HD. TEM image of the OEGCG/Herceptin complex showed a 
mixture of associates of globular complexes (~ 50 nm) with various association numbers. The 
discrepancies between HD and TEM images of the complexes may be due to the difference in 
the state of complexes, as well as the analysis method. TEM analysis captured the dehydrated 
state of the complex, while DLS measured the size of the hydrated complex. The large size of 
complexes measured by DLS could also be biased by a small fraction of larger complexes. 
The subsequent addition of PEG-EGCG to the OEGCG/Herceptin complexes led to the 
formation of monodispersed spherical complexes of ~ 90 nm in HD. 
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Figure 3-1 Schematic diagram and morphology of self-assembled MNC loaded with 
Herceptin. a, Schematic diagram of the self-assembly process to form the micellar 
nanocomplexes. b, TEM images and c, size distributions of complexes observed at each step 
of self-assembly. 
 
3.3.2. Herceptin/OEGCG complex formation and its characterizations 
The complexation of Herceptin and OEGCG was studied by varying the concentration 
of each component (Figure 3-2). The size of the complex formed increased with increasing 
OEGCG concentration at a constant protein concentration. However, as the Herceptin 
concentration increased at a constant OEGCG concentration, the complex size increased up 
to a maximum, followed by a decrease with further increase in Herceptin concentration. This 
indicated that OEGCG complexed with Herceptin via non-covalent bonds bridged by 
OEGCG molecules [132, 133].  
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Figure 3-2 Formation of protein/OEGCG complexes. Size of Herceptin/OEGCG 
complexes formed. The results are reported as mean values (n = 3). 
 
To investigate the interactions in this complexation, Triton X-100, Tween 20, SDS, 
urea and NaCl were added to the complex (Figure 3-3). Complexes were efficiently 
dissociated by Triton X-100, Tween 20 and SDS due to hydrophobic competition. However, 
urea, which has the ability to participate in the formation of strong hydrogen bonds and is not 
intrinsically hydrophobic, was ineffective in dissociating the complexes in the range of 
concentrations tested. NaCl was also ineffective in dissociating the complexes. These results 
illustrated that the dominant mode of interactions between OEGCG and proteins was 
hydrophobic interactions, instead of hydrogen bonding or ionic interactions.  
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Figure 3-3 Dissociation of Herceptin/OEGCG complexes. Complex dissociation by Tween 
20 (white circles), Triton X-100 (white squares), SDS (white triangles), urea (black circles) 
and NaCl (black squares). The data points represent mean values and the error bars represent 
standard deviations (s.d.) (n = 3). 
 
The activities of proteins during the complexation and dissociation process were also 
studied. Ideally, the complexes should be able to preserve the proteins from activity loss, 
degradation and interactions with other molecules during delivery, but exert their therapeutic 
activities at the sites of delivery. Figure 3-4 demonstrates that the activities of various 
proteins were restrained by the complexation with OEGCG. However, the activities were 
fully restored when the complexes were dissociated. This result indicated that the complexes 
were able to sequester proteins to mask them from potential environmental damages or 
undesirable side effects. Their temporarily masked bioactivity could be re-established with 
the dissociation of complexes when delivered to the desired sites. 
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Figure 3-4 Masking and unmasking of bioactivities of proteins. Protein activities upon 
complexation (white bars) and dissociation (black bars) with OEGCG. Protein/OEGCG w/w 
ratio = 1. Triton X-100 (0.1%) was used as a dissociating agent. The results are reported as 
mean values and the error bars represent s.d. (n = 3). 
 
3.3.3. Herceptin MNC formation and its characterizations 
In order to construct the outer shell surrounding the core complex, PEG-EGCG was 
added to the pre-formed Herceptin/OEGCG complexes. Core complexes of different sizes 
were formed using different concentrations of OEGCG with a constant Herceptin 
concentration. PEG-EGCG was then added to these core complexes to form the outer shell of 
the MNC. When the amount of PEG-EGCG was increased above a certain concentration, 
there was a step change in the complex size, following which the complex size remained 
constant despite further increase in PEG-EGCG (Figure 3-5a).  The addition of PEG-EGCG 
to these core complexes dissociated the secondary associations, if any, forming MNCs of 
uniform size. This association phenomenon of complexes was well known in the mechanism 
of polyphenol/protein complexation. The complexes were associated, acting as nuclei by 
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bridging through polyphenol, when the polyphenol concentration was increased [120, 138]. 
The inter-complex association between nucleic Herceptin/OEGCG complexes could be 
dissociated by PEG-EGCG due to hydrophobic competition with the EGCG moieties of PEG-
EGCG. Subsequently, PEG-EGCG assembled around the Herceptin/OEGCG complexes 
under the critical PEG-EGCG concentration required to form the core-shell MNCs. The 
uniform complex size above the critical PEG-EGCG concentration could have resulted from 
repulsion against further assembly by the PEG outer shell that was formed. 
Figure 3-5b demonstrated that both the composition and the sequence of addition 
affected the construction of the MNCs. In the absence of OEGCG, PEG-EGCG still formed 
micellar complexes with Herceptin, whereas PEG did not assemble with Herceptin. However, 
Herceptin/PEG-EGCG complex was not sufficiently stable, as indicated by its dissociation 
with the post-addition of Herceptin. In contrast, the MNCs formed by the sequential two-step 
self-assemblies (i.e. the assembly of OEGCG with Herceptin, followed by the PEG-EGCG 
assembly around the Herceptin/OEGCG complex) showed no change in size despite the post-
addition of Herceptin. These results suggested that OEGCG might have played an important 
role in stabilizing the complex structure by producing a more cross-linked and hydrophobic 
core that strengthened the binding with PEG-EGCG, and the stably formed PEG shell 
isolated the core from the access of protein (Herceptin) that was subsequently added. When 
PEG-EGCG was added directly to OEGCG without the pre-complexation of OEGCG and 
Herceptin, huge complexes were obtained and the size further increased with the post-
addition of Herceptin. The PEG-EGCG and OEGCG were considered to form a complex by 
hydrogen bonding between oxygen through an ether linkage of the PEG chain and the 
phenolic hydroxyl group of the OEGCG [139], which was not reversible with the post-
addition of Herceptin. Therefore, pre-complexation of OEGCG/Herceptin (wherein OEGCG 
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chains were considered to be mostly folded) was necessary to construct the stable and 
spatially ordered MNC. 
 
 
Figure 3-5 Core-shell MNC formation. a, Complex size obtained when PEG-EGCG of 
various concentrations were added to the preformed Herceptin/OEGCG complexes at various 
OEGCG concentrations: 0.1 μg/ml (white circles), 3 μg/ml (white squares), 6 μg/ml (white 
triangles) and 12 μg/ml (black circles). The points represented mean values, and the error 
bars represented s.d. (n = 3). b, Complexes formed with various compositions and various 
adding sequences. The results are reported as mean values, and the error bars represent s.d. (n 
= 3). 
 
We also performed zeta potential measurement at each step of these two-step 
sequential self-assemblies (Figure 3-6). The surface charge of the Herceptin/OEGCG 
complexes was observed to be more positive than free Herceptin, which might indicate a 
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structural change in the protein, resulting in more positive moieties being folded to the 
surfaces through its interactions with OEGCG. After adding the required amount of PEG-
EGCG to the Herceptin/OEGCG complexes, the surface charge of the resulting complex 
decreased, suggesting that the MNCs were constructed with a PEG outer shell that 
surrounded the Herceptin/OEGCG core.  
 
 
Figure 3-6 Surface charges of the complexes observed at each assembly step. The results 
are reported as mean values and the error bars represent s.d. (n = 5). 
 
The structure of a protein delivery carrier should be stable over time under in vivo 
condition. We demonstrated that the MNCs retained their integrity and showed good stability 
in the presence of serum without size change at 37°C for 15 days (Figure 3-7a). Also, they 
did not undergo any size reduction upon a thousand-fold dilution (Figure 3-7b), showing 
excellent stability as a function of suspension dilution, which would occur in vivo.  
To investigate the protection of proteins by this system, the micellar complexes 
loaded with a fluorescence-labeled protein (FITC-Herceptin) were subjected to a protease 
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(proteinase K), and the fluorescence intensity increase due to protein degradation was 
monitored (Figure 3-8). This experiment was performed based on a self-quenching 
mechanism, whereby enzymatic cleavage of fluorophores held in close steric alignment 
would result in fluorescent activation as the fluorophores moved away from each other [140, 
141]. The fluorescence intensity of free FITC-Herceptin increased greatly with time, 
indicating the progressive protein degradation by proteinase K. In contrast, the fluorescence 
intensity of FITC-Herceptin loaded in the MNCs increased only gradually with time, 
demonstrating that the protein was protected from rapid proteolysis by this MNC system.  
 
 
Figure 3-7 MNC stability over time and dilution. a, Integrity of the MNC in the presence 
of serum at 37 °C and b, Dilution effect of MNC. The data points represent mean values and 
the error bars represent s.d. (n = 3). 
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Figure 3-8 Protection against proteolysis by complexation. Free FITC-Herceptin (white 
circles) and FITC-Herceptin loaded MNC (white squares) in the presence of proteinase K. 
The data points represent mean values and the error bars represent s.d. (n = 3). 
 
3.4. Summary 
MNCs were successfully constructed by two-step self-assemblies yielding 
monodispersed spherical complexes of ~ 90 nm in hydrodynamic diameter. 
Herceptin/OEGCG core complexes were shown to be mainly based on hydrophobic 
interactions. OEGCG was demonstrated to have the potential to protect the proteins from 
activity loss by complexation, and the protein activity could be re-established upon 
dissociation of the complexes. The formation of Herceptin/OEGCG core complex prior to the 
addition of PEG-EGCG was necessary to construct stable and spatially ordered MNCs. The 
structure of the MNCs was further confirmed by zeta potential study, which showed a 
significant decrease in the surface charge of Herceptin/OEGCG complex upon addition of 
PEG-EGCG. MNCs were also shown to possess high stability over time and dilution, which 
would be beneficial during protein delivery. We further demonstrated that the MNC structure 
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was able to protect the proteins from enzyme degradation. With all these qualities, the MNCs 
were expected to be a desirable protein delivery system. In the following chapters, Herceptin 
MNCs would be assessed for their efficacy in improving the anticancer effect of Herceptin 
both in vitro and in vivo through a combinatorial therapeutic effect between the carrier and 
the protein. 
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Chapter 4 – Anticancer Effect of Herceptin Micellar 
Nanocomplexes In Vitro 
 
4.1. Introduction 
A micellar nanocomplex (MNC) comprising of Herceptin and EGCG derivatives (i.e. 
OEGCG and PEG-EGCG) was developed in the previous chapters. Herceptin (trastuzumab) 
is a humanized monoclonal antibody (mAb) directed against the extracellular domain of the 
tyrosine kinase receptor HER2. Herceptin has been shown to inhibit the proliferation of 
HER2-dependent tumors. It is approved by the Food and Drug Administration (FDA) for 
patients with invasive breast cancers that overexpress HER2, in both the metastatic and the 
adjuvant setting [116, 125]. HER2 is overexpressed in 25–30% of human breast cancer 
patients, and has been shown as an adverse prognostic factor. HER2 overexpression is 
frequently associated with disease relapse and overall patient survival [142, 143]. 
Epigallocatechin-3-gallate (EGCG), the major polyphenolic compound found in green 
tea, has been recognized to possess various therapeutic efficacies including anticancer effect  
which was demonstrated in numerous human, animal and in vitro studies [2, 5, 124]. Many 
mechanisms for the anticancer activities of EGCG have been proposed including growth 
arrest and apoptosis, and inhibition of angiogenesis and metastasis through regulation of 
multiple signaling pathways [109]. 
Herceptin-MNC has been shown to possess high stability over time and with dilution, 
as well as to protect against enzymatic degradation in the previous chapter. In this chapter, 
Herceptin-MNC was assessed for its therapeutic efficacy in vitro. The cytotoxicity of EGCG 
derivatives on normal and cancer cells was investigated. We then formulated Herceptin-MNC 
of various compositions of OEGCG and PEG-EGCG, and examined their efficacies in 
inhibiting cancer cell growth. Based on the results, a composition of Herceptin-MNC was 
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selected to further study its anticancer effect on various cancer cell lines, including HER2-
overexpressing cancer cells (e.g. BT-474, SKBR-3 and SKOV-3) and non HER2-
overexpressing normal cells (e.g. MCF-10A and HMEC). Since Herceptin and EGCG 
derivatives that made up Herceptin-MNC displayed anticancer properties, possible synergism 
between these components on the HER2-positive cell lines was explored. We also examined 
the underlying mechanisms for the anticancer efficacy of the newly developed Herceptin-
MNC system. We then proposed possible mechanisms that could be attributed to EGCG 
derivatives and Herceptin either independently or in combination; these include: EGCG-
mediated hydrogen peroxide (H2O2) cytotoxicity, cell cycle arrest and inhibition of PI3K/Akt 
pathway. 
 
4.2. Materials and methods 
4.2.1. Cell culture 
BT-474 (HTB-20), SKBR-3 (HTB-30), SKOV-3 (HTB-77) and MCF-10A (CRL-
10317) were purchased from ATCC (USA). BT-474 cells were cultured in RPMI 1640 with 
HEPES buffer; SKBR-3 and SKOV-3 cells were cultured in Mc Coy‟s 5A media. The media 
were supplemented with 10% Fetal Bovine Serum (FBS) and 100 units/ml of penicillin and 
streptomycin. The media and supplements were purchased from Gibco. HMEC (CC-2551) 
was purchased from Lonza (USA). Both MCF-10A and HMEC were maintained in MEBM 
media supplemented MEGM BulletKit with the addition of 100 ng/ml cholera toxin for 
MCF-10A. The media and supplements were purchased from Lonza. 
 
4.2.2. Toxicity of carrier components 
The cytotoxicity of EGCG derivatives and intact EGCG was examined on HMEC. 
Cells were plated (1×10
4
 cells/well) in quintuplicate in 96-well microplates, and allowed to 
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adhere overnight. The culture media were then replaced with the media containing the 
following samples: EGCG, OEGCG, and PEG-EGCG at various concentrations (0.05 – 500 
μM of EGCG unit concentration). The cells were incubated at 37 °C in 5% CO2. After 72 h, 
the culture media were replaced with the Phenol Red-free medium containing 10% Alamar 
Blue, which is a dye that can be reduced by the cytochrome c activity of cells. Cell viability 
was determined from dye reduction by monitoring the fluorescence intensity (λ ex = 530 nm 
and λ em = 590 nm) after 4 h of incubation. 
The cancer cell growth inhibitory effect of EGCG derivatives was examined on BT-
474. Cells were plated (1×10
4
 cells/well), and treated in the same way as mentioned above. 
 
4.2.3. Cell growth inhibition study 
The cell growth inhibitory effect of various compounds including Herceptin-MNC, 
BSA-MNC, Herceptin, BSA, OEGCG and PEG-EGCG, was studied with Alamar Blue assay, 
as described in 4.2.2. 
  
4.2.3.1. Optimisation of Herceptin-MNC compositions 
To optimize Herceptin-MNC compositions, the cell growth inhibitory effect of 
Herceptin at various concentrations was first determined. BT-474 cells were seeded (1×10
4
 
cells/well) in quintuplicate in 96-well microplates, and allowed to adhere overnight. The cells 
were treated with Herceptin dissolved in media (1×10
-4
 – 50 mg/ml) for 72 h prior to Alamar 
Blue assay. 
Herceptin-MNC was then formulated using the optimized Herceptin concentration 
with different OEGCG and PEG-EGCG concentrations. BT-474 cells were treated with 
Herceptin-MNC or BSA-MNC of various compositions: Herceptin or BSA = 0.5 mg/ml, 
OEGCG = 12 – 146 μg/ml (or 25 – 300 μM of EGCG unit concentration) and PEG-EGCG = 
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65 – 783 μg/ml (or 25 – 300 μM of EGCG unit concentration). After 72 h, the cell viability 
was assessed by Alamar Blue assay. 
 
4.2.3.2. Cell growth inhibitory effect of Herceptin-MNC on various cell lines 
BT-474, SKBR-3, SKOV-3, MCF-10A and HMEC cells were each seeded (1×10
4
 
cells/well) in quintuplicate in 96-well microplates, and allowed to adhere overnight. The cells 
were treated with: Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-
EGCG = 261 μg/ml), BSA-MNC (with the equivalents of BSA, OEGCG and PEG-EGCG), 
Herceptin, BSA, OEGCG, and PEG-EGCG. After 72 h, the cell viability was determined 
using Alamar Blue assay. 
 
4.2.4. Synergy determination 
BT-474, SKBR-3 and SKOV-3 were each seeded (1×10
4
 cells/well) in quintuplicate 
in 96-well microplates, and allowed to adhere overnight. The cells were treated with: 
Herceptin (0.1 – 50 mg/ml), OEGCG (10 – 240 μg/ml) and PEG-EGCG (70 – 1360 μg/ml). 
After 72 h, Alamar Blue assay was performed. These data were converted to fraction affected 
(Fa) (where Fa = 0 represented 100% viability and Fa = 1 represented 0% viability), and 
analyzed with the Calcusyn™ (Biosoft, Ferguson, MO) based upon the Chou and Talalay 
median effect principle [144]. A combination index (CI) was calculated with this program to 
identify synergistic, additive, and antagonistic drug interactions. 
 
4.2.5. Effects of hydrogen peroxide (H2O2) on cell viability of BT-474 
BT-474 cells were each seeded (1×10
4
 cells/well) in quintuplicate in 96-well 
microplates, and allowed to adhere overnight. The cells were treated with H2O2 (0.5 – 500 
μM) for 24 h and assessed for cell viability. 
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To assess the ability of catalase and sodium pyruvate to block the effect of H2O2, BT-
474 cells were exposed to 100 μM of H2O2 in the presence or absence of catalase (100 U/ml) 
or sodium pyruvate (1 mM). After 24 h, the cell viability was measured by Alamar Blue 
assay. 
 
4.2.6. Quantification of H2O2  
The quantification of H2O2 was performed using Quantitative Peroxide assay kit 
(Pierce, Thermo Scientific) according to manufacturer‟s protocol. H2O2 (100 μM) was added 
to PBS in the presence or absence of catalase (100 U/ml) or sodium pyruvate (1 mM). The 
H2O2 concentration was quantified 24 h later. 
 
4.2.7. Effects of EGCG, OEGCG and PEG-EGCG on BT-474 cell viability 
BT-474 cells were seeded (1×10
4
 cells/well) in quadruplicate in 96-well microplates, 
and allowed to adhere overnight. The cells were treated with 100 μM of EGCG, OEGCG or 
PEG-EGCG in the presence or absence of catalase (100 U/ml) or sodium pyruvate (1 mM). 
After 24 h, the cell viability was measured by Alamar Blue assay.  
 
4.2.8. Quantification of EGCG-mediated H2O2 generation 
The measurement of H2O2 generation mediated by EGCG was performed using 
Quantitative Peroxide assay kit (Pierce, Thermo Scientific) according to manufacturer‟s 
protocol. One hundred eleven μM of EGCG or OEGCG or PEG-EGCG was prepared in 
deionized water in the presence or absence of catalase (100 U/ml) or sodium pyruvate (1 
mM). 10× PBS was then added to the samples to start the oxidation reaction which generated 
H2O2. The final concentration of EGCG or its derivatives was 100 μM of EGCG unit 
concentration. The H2O2 generated was measured after 24 h.  
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4.2.9. Effects of EGCG-mediated H2O2 cytotoxicity by MNC on BT-474 cell viability 
BT-474 cells were seeded (1×10
4
 cells/well) in quadruplicate in 96-well microplates, 
and allowed to adhere overnight. The cells were treated with: Herceptin-MNC (Herceptin = 
0.5 mg/ml, OEGCG = 24 μg/ml, PEG-EGCG = 261 μg/ml), BSA-MNC (with the equivalents 
of BSA, OEGCG and PEG-EGCG), Herceptin and BSA in the presence or absence of 
catalase (100 U/ml) or sodium pyruvate (1 mM). After 24 h, the cell viability was measured 
by Alamar Blue assay. Quantification of H2O2 generated by the compounds was performed 
according to the method described in 4.2.8. 
 
4.2.10. Cell cycle assay 
For cell cycle analysis, BT-474 cells were seeded (6.5×10
5
 cells) in 60 mm tissue 
culture dish, and allowed to adhere overnight. The media were then removed and replaced 
with serum-free media overnight before treatment. The cells were treated with the following 
compounds: Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-EGCG = 
261 μg/ml), BSA-MNC (with the equivalents of BSA, OEGCG and PEG-EGCG) and 
Herceptin for 48 h. The cell culture supernatant of each sample was saved and combined with 
the harvested cells. Untreated cells served as negative control. Cells were fixed in 70% 
ethanol and stained with propidium iodide (PI) and analyzed by flow cytometry (BD LSR II) 
immediately. 
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4.2.11. Western-blotting 
BT-474 cells were seeded (6.5×10
5
 cells) in 60 mm tissue culture dish, and allowed to 
adhere overnight. The culture media were then replaced by the media containing the 
following samples: Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-
EGCG = 261 μg/ml), BSA-MNC (with the equivalents of BSA, OEGCG and PEG-EGCG), 
Herceptin, BSA, OEGCG and PEG-EGCG. The cells were incubated at 37 °C in 5% CO2. 
After 4 h, the cells were washed in PBS before being harvested in RIPA buffer (150 mM of 
NaCl, 1.0% IGEPAL
®
 CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate 
(SDS), and 50 mM of Tris, pH 8.0, Sigma Aldrich) supplemented with 40 μg/ml protease 
inhibitor cocktail (Roche) and 10 μg/ml of phosphatase inhibitor (EMD Biosciences). The 
concentration of cell lysates was determined by BCA Protein Assay Kit (Thermo Scientific). 
Samples were prepared for loading on sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) in Laemmli sample buffer and boiled for 5 mins. The proteins 
were separated using 10% SDS-PAGE and transferred onto Immobilon
®
-FL polyvinylidene 
difluoride (PVDF) membrane (Millipore) using an electrophoresis system (BioRad). 
Immunoblots were blocked with 5% non-fat dry milk in Tris-buffered saline with 0.05% 
Tween-20 (TBS-T) (Sigma-Aldrich) for 1 h at room temperature. They were then incubated 
with the appropriate primary antibody (diluted in 5% non-fat dry milk in TBS-T) overnight at 
4°C. It was followed by incubation with the appropriate secondary antibodies (diluted in 5% 
non-fat dry milk in TBS-T) for 1 h at room temperature. Proteins were detected using 
Immobilon™ Western Chemiluminescent HRP Substrate System (Millipore), and developed 
on X-ray film using Kodak SRX2000 Developer (Rochester, NY, USA). 
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4.2.12. Surface HER-2 quantification 
BT-474 cells were seeded (3×10
5
 cells/well) in 6-well plate, and allowed to adhere 
overnight. The culture media were then replaced by the media containing the following 
samples: Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-EGCG = 261 
μg/ml) and Herceptin. The cells were incubated at 37 °C in 5% CO2. After 4 h, the cells were 
washed in PBS and harvested in 10 mM ethylenediaminetetraacetic acid (EDTA). Cell 
culture media were added to the cells before centrifuging at 1000 rpm for 3 min. The cells 
were washed with ice cold PBE (PBS, 2% BSA, 1 mM EDTA) before Alexa Fluor
®
 488 anti-
HER2 antibody (Biolegend) or Alexa Fluor
®
 488 IgG1, K isotype  (Biolegend) was added. 
The cells were incubated for 30 min on ice and washed three times with PBE. Some of the 
control (untreated) cells were unstained and be represented as blank. The cells were then 
resuspended in 4% parafolmaldehyde (PFA), and kept at 4 °C before being analyzed by flow 
cytometry (BD FACSCalibur). 
 
4.2.13. Immunofluorescence Microscopy 
BT-474 cells were seeded (6×10
4
 cells/well) on coverslip in 24-well plate, and 
allowed to adhere overnight. The culture media were then replaced by the media containing 
the following samples: Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-
EGCG = 261 μg/ml) and Herceptin. The cells were incubated at 37 °C in 5% CO2. After 4 h, 
the cells on coverslip were washed in PBS, and fixed in 4% PFA for 20 min at room 
temperature. The cells were then washed and incubated in PBS containing 50 mM of NH4Cl 
for 5 min at room temperature. They were permeabilized by incubation in a mixture of PBS, 
2% FBS and 0.05% saponin (PSS) for 5 min at room temperature. They were then incubated 
with the appropriate antibody diluted in PSS for 30 min in a wet chamber in the dark. The 
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coverslips were then washed 3 times with PSS and 2 times with PBS, and mounted on glass 
slides with ProLong
®
 Gold antifade reagent with DAPI (Molecular Probes). 
 
4.2.14. Antibodies 
The primary and secondary antibodies used for the western-blot (WB) analysis, flow 
cytometry (FACS) and immunofluorescence microscopy (IFM) experiments are shown in 
Table 4-1. 
 
Table 4-1 Details of the antibodies used for WB, FACS and IFM experiments 
Primary antibody Company Secondary antibody Technique 
Anti-HER2 Calbiochem Polyclonal goat anti-mouse WB 
Anti-pHER2 R&D Sstems Polyclonal goat anti-rabbit WB 
Anti-Akt Cell Signalling Polyclonal goat anti-rabbit WB 
Anti-pAkt (S473) Cell Signalling Polyclonal goat anti-rabbit WB, IFM 
Anti-α-calnexin Stressgen Polyclonal goat anti-rabbit WB 
Alexa Fluor
®
 488 anti-HER2 Biolegend Not applicable FACS, IFM 
Alexa Fluor
®
 488 IgG1, K isotype Biolegend Not applicable FACS, IFM 
 
4.2.15. Statistical analysis 
The anticancer effect was analyzed by Student t-test. p < 0.05 was the minimum 
requirement for a statistically significant difference. 
 
4.3. Results and discussion 
4.3.1. Selective cancer cell growth inhibitory effect of EGCG derivatives 
To assess the toxicity of the carrier components (i.e. OEGCG and PEG-EGCG) to the 
normal tissues, cytotoxicity of EGCG derivatives and EGCG was examined on HMEC over a 
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wide range of concentrations (0.05 – 500 µM of EGCG unit concentrations). Figure 4-1a 
shows that PEG-EGCG did not affect cell growth in the range of concentrations tested. Like 
EGCG, OEGCG showed no cytotoxicity below 100 µM, and a low cytotoxicity at 100 µM or 
higher. This indicates that oligomerization and conjugation of PEG to EGCG did not increase 
its cytotoxicity to normal tissues. 
 
 
Figure 4-1 Selective cell growth inhibitory effect of EGCG derivatives. a, HMEC and b, 
BT-474 (HER2-overexpressing human breast cancer cell line) were treated with  EGCG 
(white circles), OEGCG (white squares) and PEG-EGCG (white triangles) for 72 h. The data 
points represent mean values and the error bars represent standard deviation (s.d.) (n = 5). 
 
To investigate the cancer cell growth inhibitory effect of the EGCG derivatives, BT-
474 cells were exposed to OEGCG and PEG-EGCG for a period of 3 days. Upon exposure, 
both OEGCG and PEG-EGCG inhibited cancer cell growth in a concentration-dependent 
manner (Figure 4-1b). These results demonstrated that EGCG derivatives selectively inhibit 
the growth of cancer cells, but not normal cells.  
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4.3.2. In vitro anti-cancer activity of MNC loaded with Herceptin (trastuzumab) 
4.3.2.1. Optimization of Herceptin-MNC 
To achieve the optimal effect of Herceptin-MNC, the micelle composition was 
optimized in vitro. Herceptin was shown to exert moderate cell growth inhibitory effect on 
the cells in a dose dependent manner (Figure 4-2). It demonstrated ~ 70% cell viability of 
BT-474 upon Herceptin treatment over a wide concentration range of 0.003 – 12.5 mg/ml. It 
caused higher cell growth inhibition when Herceptin concentration was increased beyond 
12.5 mg/ml.  
Thus, 0.5 mg/ml of Herceptin was used to form Herceptin-MNC of various 
compositions (see Table 4-2) to assess for their cell growth inhibition effect on BT-474 cells.  
Generally, the cell growth inhibition effect of Herceptin-MNC and BSA-MNC increased with 
increasing PEG-EGCG concentration (Figure 4-3a). In contrast, OEGCG concentration in 
Herceptin-MNC and BSA-MNC had a minor influence on cell growth inhibition in a dose 
dependent manner (Figure 4-3b). Herceptin-MNC, made up of Herceptin, OEGCG and PEG-
EGCG, showed a combination cell growth inhibition effect contributed by both Herceptin 
and EGCG derivatives. The BSA-MNC control showed a cell growth inhibition effect due to 
EGCG derivatives alone, since BSA is not a therapeutic protein. BSA-MNC containing low 
PEG-EGCG concentration irrespective of OEGCG concentration did not show any cell 
growth inhibition effect. However, with increasing concentration of PEG-EGCG in the BSA-
MNC, the cell growth inhibition effect increased. This indicated that the carriers (i.e. EGCG 
derivatives) provided a therapeutic efficacy. Hence, Herceptin-MNC demonstrated a 
combination effect of the EGCG derivatives and Herceptin. 
The subsequent studies on the anticancer effect of Herceptin-MNC were conducted 
with the following formulation: 0.5 mg/ml of Herceptin, 24 µg/ml of OEGCG (50 µM of 
EGCG unit concentration) and 261 µg/ml of PEG-EGCG (100 µM of EGCG unit 
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concentration). At these concentrations, each component of MNC showed low-to-moderate 
cell growth inhibition effect on BT-474, while Herceptin-MNC demonstrated significantly 
higher cell growth inhibition effect (Figure 4-1b, Figure 4-2 and Figure 4-3). 
 
 
Figure 4-2 Cell growth inhibitory effect of Herceptin. The data points represent mean 
values, and the error bars represent s.d. (n = 5). 
 
Table 4-2 Compositions of Herceptin-MNC 
  OEGCG 
  25 µM 50 µM 100 µM 200 µM 300 µM 
P
E
G
-E
G
C
G
 25 µM      
50 µM      
100 µM      
300 µM      
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Figure 4-3 Cell growth inhibitory effect of various formulations of Herceptin-MNC and 
BSA-MNC on BT-474 breast cancer cells. a, Cells were treated for 72 h with Herceptin-
MNC (Herceptin = 0.5 mg/ml, OEGCG = 50 μM of EGCG unit concentration, PEG-EGCG = 
25–300 μM of EGCG unit concentration, white circles) and BSA-MNC (BSA = 0.5 mg/ml, 
OEGCG = 50 μM of EGCG unit concentration, PEG-EGCG = 25–300 μM of EGCG unit 
concentration, white squares). b, Cells were treated for 72 h with Herceptin-MNC (Herceptin 
= 0.5 mg/ml, OEGCG = 25–300 μM of EGCG unit concentration, PEG-EGCG = 100 μM of 
EGCG unit concentration, white circles) and BSA-MNC (BSA = 0.5 mg/ml, OEGCG = 25–
300 μM of EGCG unit concentration, PEG-EGCG = 100 μM of EGCG unit concentration, 
white squares). The data points represent mean values, and the error bars represent s.d. (n = 
4). The data of Herceptin-MNC and BSA-MNC were significantly different with p < 0.001.  
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4.3.2.2. Cell growth inhibitory effect on HER2-overexpressing cancer cells 
The anticancer effect of Herceptin-MNC was studied in vitro on different cell lines 
and compared to that of free Herceptin. The cancer cell growth inhibitory effect was observed 
on HER2-overexpressing cancer cells (e.g. BT-474 (human breast cancer cells), SKBR-3 
(human breast cancer cells) and SKOV-3 (human ovarian cancer cells)) after treatment with 
Herceptin, Herceptin-MNC, BSA-MNC (drug-free carrier) or an equivalent amount of each 
carrier component (OEGCG and PEG-EGCG) (Figure 4-4). Herceptin-MNC showed a 
significantly higher inhibitory effect than Herceptin, indicating the combined cell growth 
inhibitory effect of the EGCG derivatives and Herceptin on BT-474, SKBR-3 and SKOV-3. 
Since the MNCs were formed mainly via hydrophobic interaction and would dissociate by 
hydrophobic competition with surfactants, it is possible that they gradually dissociate and 
release components by interaction with bio-amphiphilic molecules, e.g. lipids of cell 
membrane, when they were retained by cells. 
 
4.3.2.3. Cytotoxicity on non-cancerous cells 
Herceptin-MNC showed no cytotoxicity to MCF-10A (human mammary epithelial 
cell line) and HMEC (Figure 4-5). No decrease of cell viability was observed on MCF-10A 
and HMEC cells treated with EGCG derivatives and Herceptin. Herceptin-MNC was shown 
to exert selective anticancer effect on HER2-overexpressing cancer cells and did not cause 
significant cytotoxicity on normal cells (non HER2-overexpressing cells). Therefore, it is less 
likely to cause undesirable effect on the normal tissue. 
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Figure 4-4 Cell growth inhibitory effect on HER2-overexpressing cancer cells. Effect of 
Herceptin (0.5 mg/ml), Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 50 µM of EGCG 
unit concentration, PEG-EGCG = 100 µM of EGCG unit concentration), BSA-MNC (drug-
free carrier, with the equivalents), OEGCG and PEG-EGCG (carrier components, with the 
equivalents), BSA and control (untreated) on a, BT-474, b, SKBR-3 and c, SKOV-3 cells. 
Cell viability was assayed 72 h after the treatment. n = 5 (mean ± s.d.). * p < 0.001.  
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Figure 4-5 Effect of Herceptin-MNC on non-cancerous cells. Effect of Herceptin (0.5 
mg/ml), Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 50 µM of EGCG unit 
concentration, PEG-EGCG = 100 µM of EGCG unit concentration), BSA-MNC (drug-free 
carrier, with the equivalents), OEGCG and PEG-EGCG (carrier components, with the 
equivalents), BSA and control (untreated) on a, MCF-10A b, HMEC. Cell viability was 
assayed 72 h after the treatment. n = 5 (mean ± s.d.). 
 
4.3.3. Synergism between Herceptin and EGCG derivatives carriers 
To quantify the combined therapeutic effect of protein and the carrier components i.e. 
Herceptin and EGCG derivatives (OEGCG and PEG-EGCG), we adopted the combination 
index (CI) Theorem by Chou and Talalay [144]. CI is a term used to quantify the synergism 
or antagonism for multiple drugs. The general equation for n-drug combination at x% effect 
is described as 
     
  ∑
    
     
 
   
 
where      
  is the combination index for n drugs at x% drug effect. CI < 1, = 1, and > 1 
indicate synergism, additive effect, and antagonism, respectively.      is the concentrations 
of n drugs used in combination to achieve x% drug effect.       is the concentrations of each 
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drug alone to achieve the same effect. Based on this theory, the computer software 
(CalcuSyn) was developed for automated data analysis [145].  
The formula for calculating CI would be adapted as follows in our case: 
   
            
             
 
        
         
 
           
            
 
where (D)Herceptin, (D)OEGCG and (D)PEG-EGCG are the concentrations of Herceptin, OEGCG and 
PEG-EGCG used in combination to achieve x% drug effect. The combinative therapeutic 
effects of Herceptin and the carrier components were investigated on human breast cancer 
cells (e.g. BT-474, SKBR-3) and human ovarian cancer cell (e.g. SKOV-3). The CI of these 
systems was automatically computed by the Calcusyn software. 
 
4.3.3.1. BT-474 HER2-overexpressing human breast cancer cells 
Figure 4-6a shows the fraction of BT-474 cells affected in vitro by OEGCG, PEG-
EGCG and Herceptin at various concentrations. Herceptin-MNC (Herceptin = 0.5 mg/ml, 
OEGCG = 24 μg/ml (50 µM of EGCG unit concentration), PEG-EGCG = 261 μg/ml (100 
µM of EGCG unit concentration)) resulted in a fractional effect of 0.54 on BT-474 cells 
(Figure 4-4a). 
The specific formula for calculating CI as applied to our case is as follows: 
   
            
              
 
        
          
 
           
             
 
where (D)Herceptin, (D)OEGCG and (D)PEG-EGCG are the concentrations of Herceptin, OEGCG and 
PEG-EGCG used in combination to achieve 54% drug effect. (D54)Herceptin, (D54)OEGCG and 
(D54)PEG-EGCG are the concentrations for Herceptin, OEGCG and PEG-EGCG to achieve the 
same effect independently. The resulting CI of Herceptin-MNC was 0.86 (CI < 1), 
demonstrating the synergistic therapeutic effect between Herceptin and the carrier 
components on BT-474 cells.  
Chapter 4: Anticancer effect of Hereptin micellar nanocomplexes in vitro 
 
 80 
 
4.3.3.2. SKBR-3 HER2-overexpressing human breast cancer cells 
Figure 4-6b shows the fraction of SKBR-3 cells affected in vitro by OEGCG, PEG-
EGCG and Herceptin at various concentrations. Herceptin-MNC (Herceptin = 0.5 mg/ml, 
OEGCG = 24 μg/ml (50 µM of EGCG unit concentration), PEG-EGCG = 130.5 μg/ml (50 
µM of EGCG unit concentration)) resulted in a fractional effect of 0.82 on SKBR-3 cells 
(Figure 4-4b). Using Calcusyn, the CI for the effect of Herceptin-MNC on SKBR-3 was 
computed to be 0.10 (CI < 1), demonstrating the synergistic therapeutic effect between 
Herceptin and the carrier components on SKBR-3 cells. 
 
4.3.3.3. SKOV-3 HER2-overexpressing human ovarian cancer cells 
Figure 4-6c shows the fraction of SKOV-3 cells affected in vitro by OEGCG, PEG-
EGCG and Herceptin at various concentrations. Herceptin-MNC (Herceptin = 0.5 mg/ml, 
OEGCG = 24 μg/ml (50 µM of EGCG unit concentration), PEG-EGCG = 261 μg/ml (100 
µM of EGCG unit concentration)) resulted in a fractional effect of 0.93 on SKOV-3 cells and 
combination index was computed to be 0.87 (CI < 1) (Figure 4-4c). The result demonstrated 
the synergistic therapeutic effect between Herceptin and the carrier components on SKOV-3 
cells. 
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Figure 4-6 Effect of Herceptin and carrier components on HER2-overexpressing cancer 
cells. Effect of different doses of Herceptin (white circles), OEGCG (white squares) and 
PEG-EGCG (white triangles) on a, BT-474, b, SKBR-3 and c, SKOV-3 cells. n = 5 (mean ± 
s.d.). 
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4.3.4. Possible mechanisms that govern the anticancer effect of Herceptin-MNC 
4.3.4.1. EGCG-mediated hydrogen peroxide (H2O2) cytotoxicity 
Plant polyphenols are naturally occurring antioxidants, but they also exhibit 
prooxidant properties [146]. Being strong antioxidants, tea polyphenols are strong metal ion 
chelators. For example, the chelation of free Fe
3+
 ions prevents the formation of reactive 
oxygen species (ROS) [92]. Tea polyphenols can trap reactive species such as superoxide 
radical, singlet oxygen, hydroxyl ROS, nitric oxide, nitrogen dioxide, and peroxynitrite. The 
vicinal dihydroxy or trihydroxy structures contribute to these antioxidative activities of tea 
polyphenols also make these compounds susceptible to air oxidation under alkaline or even 
neutral pH. In the case of EGCG, the autooxidation leads to the generation of superoxide 
anion and H2O2 [93]. ROS are known to produce oxidative stress and cause damage to DNA 
and other cellular molecules [147, 148]. The ROS pathway is illustrated in Figure 4-7. The 
effect of EGCG-induced ROS-related apoptosis can be blocked completely or partially by 
catalase or sodium pyruvate [93, 149-152].  
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Figure 4-7 Major ROS pathways and antioxidant defences. Reactions shown are not 
stoichiometrically balanced and only some of the main pathways are shown. GSH = reduced 
glutathione; GSSG = oxidised glutathione; SOD = superoxide dismutase. Figure reproduced 
with permission from [148]. Copyright (1996) Elsevier. 
 
To study the effect of EGCG-mediated H2O2 cytotoxicity, BT-474 cells were exposed 
to exogenous H2O2. Exogenous H2O2 was shown to induce dose-dependent cytotoxicity on 
BT-474 cells (Figure 4-8a). At 100 µM of H2O2, 94% cell death was observed (Figure 4-8b). 
However, in the presence of catalase (100 U/ml) or sodium pyruvate (1 mM), the cytotoxicity 
of H2O2 was completely abolished because catalase and sodium pyruvate scavenged the H2O2 
administered (Figure 4-8b and c). Catalase and sodium pyruvate did not cause any 
cytotoxicity to the cells (see Figure 4-8b).  
EGCG has been reported to induce apoptosis by generation of ROS, especially H2O2, 
mainly due to the reduction of Fe(III) to Fe(II) to trigger the Fenton reaction [H2O2 + Fe(II) 
→ OH• + OH- + Fe(III)  [153]. To understand if OEGCG and PEG-EGCG killed the cells via 
the same pathway, BT-474 cells were exposed to EGCG, OEGCG or PEG-EGCG in the 
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presence and absence of catalase or sodium pyruvate. When BT-474 cells were exposed to 
EGCG (100 µM), high cytotoxicity was observed because it generated a cumulative 218 µM 
of H2O2 during the 24-h treatment period (Figure 4-9a and b). With catalase or sodium 
pyruvate, the H2O2 generated was completely eliminated, and hence no cytotoxicity was 
observed. OEGCG and PEG-EGCG were shown to exert moderate cytotoxicity on the cells 
and generated 108 and 84 µM of H2O2, respectively (Figure 4-9c, d, e and f). Catalase and 
sodium pyruvate successfully eliminated the cytotoxicity effect caused by both OEGCG and 
PEG-EGCG. These results indicated that EGCG, OEGCG and PEG-EGCG caused cell death 
via the ROS generation pathway. 
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Figure 4-8 Effects of H2O2 on cell viability of BT-474 cells. a, Cells were treated with H2O2 
of various concentrations for 24 h before the viability was determined by alamar blue. n = 5 
(mean ± s.d.). b, Cells were treated with H2O2 (100 µM) in the presence or absence of 
catalase (100 U/ml) or sodium pyruvate (1 mM). n = 4 (mean ± s.d.). c, H2O2 was scavenged 
by catalase (100 U/ml) or sodium pyruvate (1 mM). n = 2 (mean ± s.d.). 
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Figure 4-9 Effect of EGCG, OEGCG and PEG-EGCG on cell viability of BT-474 cells in 
the presence and absence of catalase or sodium pyruvate. Effect of EGCG (100 µM) on a, 
cell viability and b, H2O2 production. Effect of OEGCG (100 µM of EGCG unit 
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concentration) on c, cell viability and d, H2O2 production. Effect of PEG-EGCG (100 µM of 
EGCG unit concentration) on e, cell viability and f, H2O2 production. Cell viability study was 
performed in quadruplicate, and data were represented as mean ± s.d. Quantification of H2O2 
concentration was performed in duplicate, and data were represented as mean ± s.d.  
 
The anticancer effect of Herceptin on BT-474 cells was unaltered in the presence of 
catalase and sodium pyruvate, indicating that Herceptin did not exert anticancer effect on the 
cells via the ROS pathway (Figure 4-10). However, the effect of Herceptin-MNC on the cells 
was partially blocked by both catalase and sodium pyruvate. Herceptin-MNC in the absence 
of catalase and sodium pyruvate showed high cell growth inhibition on BT-474 cells, but the 
anticancer effect contributed by OEGCG and PEG-EGCG was removed by catalase and 
sodium pyruvate with the elimination of H2O2. This effect was further proven with BSA-
MNC, whereby the impact on cells was completely removed with the riddance of the H2O2 
generated. 
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Figure 4-10 Effect of treatment on the viability of BT-474 cells in the presence and 
absence of catalase or sodium pyruvate. a, Cell viability of Herceptin (0.5 mg/ml), 
Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 50 µM of EGCG unit concentration, 
PEG-EGCG = 100 µM of EGCG unit concentration), BSA-MNC (drug-free carrier, with the 
equivalents), BSA and control (untreated) in the presence and absence of catalase (100 U/ml) 
or sodium pyruvate (1 mM), n = 4 (mean ± s.d.), and b, the corresponding H2O2 production, n 
= 2 (mean ± s.d.). 
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4.3.4.2. Cell cycle arrest 
Many reports have shown that one of the mechanisms that govern the anticancer 
effect of Herceptin was cell cycle arrest at G1 phase [116, 154]. EGCG was also known to 
induce cell growth arrest [109, 155, 156]. Herceptin-MNC composed of Herceptin, OEGCG 
and PEG-EGCG is likely to exhibit a high level of growth arrest due to the components 
combinational effect. Flow cytometry revealed that Herceptin induced BT-474 cell cycle 
arrest with an increased fraction of G1 phase cells (from 75.9% to 90.3%) and a reduced 
fraction of S phase cells (from 18.2% to 4.7%) (Figure 4-11). BSA-MNC was found to 
induce minor cell growth arrest by increasing the G1 phase cells from 75.9% to 81.8%, and 
reduced S phase cells from 18.2% to 13.4%. This confirmed that both Herceptin and EGCG 
derivatives (i.e. OEGCG and PEG-EGCG) induced growth arrest. When BT-474 cells were 
treated with Herceptin-MNC, the fraction of cells in G1 phase increased from 75.9% to 
89.6%, and the fraction of cells in S phase reduced from 18.2% to 3.1%. In summary, 
Herceptin and Herceptin-MNC were both very efficient in arresting cell growth. 
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Figure 4-11 Cell-cycle distribution of BT-474 cells upon Herceptin-MNC treatment. BT-
474 cells were treated for 48 h with Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 50 
µM of EGCG unit concentration, PEG-EGCG = 100 µM of EGCG unit concentration), BSA-
MNC (drug-free carrier, with the equivalents), Herceptin, and the control (untreated). The 
panels are representative of three independent experiments. 
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4.3.4.3. HER2 down-regulation 
One of the postulate mechanisms of Herceptin is the down-regulation of HER2 and its 
subsequent degradation in HER2-overexpressing breast cancer [125, 157]. Overexpression of 
HER2 is known to relate to cell proliferation and survival. Down-regulation of HER2 is 
therefore believed to arrest the growth and eventually induce apoptosis. To study if our 
treatment affect the phosphorylated form of HER2 (pHER2) and total HER2, we performed 
Western blot and flow cytometry (FACS) on treated BT-474 cells. Western blot results 
showed no major down-regulation of both pHER2 and total HER2 by Herceptin, Herceptin-
MNC and other compounds (Figure 4-12a). Furthermore, only minor down-regulation of 
surface HER2 was observed on the cells treated with Herceptin and Herceptin-MNC (Figure 
4-12b). Gennari et al. indicated in his report that no significant down-regulation of HER2 was 
seen in breast cancer patients who achieved tumor response to 4 weeks of Herceptin given 
before the surgery [158]. This suggests that HER2 level upon treatment is not directly 
correlated to the treatment outcome. 
Since there was only minor down-regulation of HER2 and pHER2 in both Western 
blot and flow cytometry (FACS) analysis, we investigated if the treatment altered the 
distribution of HER2 by immunofluorescence microscopy (IFM). Immunofluorescence 
staining of HER2 in the untreated (control) cells showed that the receptors were uniformly 
distributed on the cell surface with some internalization into the cytosol (Figure 4-12c). No 
difference of HER2 receptors distribution was observed in the cells treated with Herceptin for 
4 h as compared to the control. In addition, no down-regulation of HER2 receptors was 
observed on the cells treated for 8 h and 24 h (see Appendix G). Both Herceptin and 
Herceptin-MNC did not cause any down-regulation of HER2 receptors as well as alteration in 
the HER2 distribution. 
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Figure 4-12 Herceptin-MNC treatment does not affect the expression of HER-2 
receptors and its signalling in BT-474 cells. a, Western blot analysis of phosphorylated and 
total HER-2 upon 4-h treatment of Herceptin (0.5 mg/ml), Herceptin-MNC (Herceptin = 0.5 
mg/ml, OEGCG = 50 µM of EGCG unit concentration, PEG-EGCG = 100 µM of EGCG unit 
concentration), BSA-MNC (drug-free carrier, with the equivalents), OEGCG and PEG-
EGCG (carrier components, with the equivalents), BSA and control (untreated). b, Flow 
cytometry histogram representation of total surface HER2 upon 4-h treatment with the above 
compounds. c, Immunofluorescence staining of HER2 upon 4-h treatment. Green: HER2, 
blue:DAPI. 
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4.3.4.4. Inhibition of PI3K/Akt pathway 
Activation of the PI3K/Akt pathway is one of the most studied processes downstream 
of HER2 activation [116, 159] (Figure 4-13). PI3K is composed of an 85-kDa regulatory 
subunit and a 110-kDa catalytic subunit, stably bound to each other and inactive in quiescent 
cells. Upon activation by HER2, p85 binding to receptor tyrosine kinases including HER2 
relieves the p110α catalytic unit to relocate at the plasma membrane. Next, p110α 
phosphorylates there and converts phosphatidylinositol (4,5)-bisphosphate (PIP2) into 
phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 acts as a docking site for Akt and 
phosphatidylinositol-dependent kinase 1 (PDK1). At the membrane, Akt bound to PIP3 
becomes phosphorylated at threonine 308 and serine 473. 
 
 
Figure 4-13 Schematic of HER2-related PI3K/Akt pathway. Figure reproduced with 
permission from [159]. Copyright (2009) American Association for Cancer Research. 
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Hyperactivation of Akt is associated with resistance to apoptosis, increased cell 
growth and cellular energy metabolism [109]. Therefore, Akt contributes to tumor growth 
and progression. PI3K (phosphoinositide-3-kinase) is activated by HER2 overexpression/ 
activation [116]. Both Herceptin and EGCG are known to inhibit the PI3K pathway. Western 
blot analysis of phosphorylated Akt (pAkt) and total Akt demonstrated that Herceptin 
treatment resulted in a reduction of the pAkt signal, whereas no decrease in the total Akt was 
observed (Figure 4-14a). This suggested that Herceptin decreased the activity of the Akt 
protein and did not down-regulate the Akt protein. Herceptin-MNC comprised of Herceptin, 
OEGCG and PEG-EGCG showed the highest inhibition of the Akt activity, with no change in 
total Akt protein. The down-regulation of pAkt by Herceptin and Herceptin-MNC was further 
confirmed by immunofluorescence staining of pAkt (S473) (Figure 4-14b, Appendix H).  
To further investigate if down-regulation of pAkt by Herceptin-MNC was partially 
mediated by the ROS pathway, cells were treated with Herceptin-MNC in the presence of 
catalase, which eliminated the ROS pathway. Figure 4-14a shows that the effect of 
Herceptin-MNC on pAkt was reduced to a level similar to Herceptin treatment. The result 
indicated that Herceptin-MNC down-regulated pAkt partially via ROS pathway, which 
suggested that ROS pathway could be related to the inhibition of Akt signalling. 
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Figure 4-14 Herceptin-MNC treatment down-regulated the phosphorylation of Akt 
(serine 473) (pAkt (S473)) in BT-474 cells. a, Western blot analysis of pAkt (S473) and 
total Akt upon 4-h treatment with Herceptin (0.5 mg/ml), Herceptin-MNC (Herceptin = 0.5 
mg/ml, OEGCG = 50 µM of EGCG unit concentration, PEG-EGCG = 100 µM of EGCG unit 
concentration), BSA-MNC (drug-free carrier, with the equivalents), OEGCG and PEG-
EGCG (carrier components, with the equivalents), BSA and control (untreated). b, 
Immunofluorescence staining of pAkt (S473) upon 4-h treatment. Magenta: pAkt (S473), 
blue:DAPI. 
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4.4. Summary 
In summary, EGCG derivatives (i.e. OEGCG and PEG-EGCG) selectively exerted 
growth inhibitory effect on cancer cells but not normal cells. Herceptin was also shown to 
moderately inhibit BT-474 cell growth over a wide concentration range. Upon optimization, 
Herceptin-MNC composition was fixed at Herceptin = 0.5 mg/ml, OEGCG = 24 µg/ml (50 
µM EGCG unit concentration) and PEG-EGCG = 261 µg/ml (100 µM EGCG unit 
concentration) for further study. This Herceptin-MNC was shown to significantly enhance the 
cell growth inhibitory effect of Herceptin on various HER2-overexpressing cell lines (i.e. BT-
474, SKBR-3 and SKOV-3), but it did not show any toxicity on normal cells (i.e. MCF-10A 
and HMEC). Therefore, MNC is likely to minimize the undesirable side effects of cancer 
treatment. Furthermore, components making up Herceptin-MNC demonstrated a synergistic 
effect on BT-474, SKBR-3 and SKOV-3. 
The mechanism study results showed that Herceptin-MNC exerted anticancer effect 
via ROS pathway contributed by EGCG derivatives. Herceptin-MNC showed strong cell 
cycle arrest effect due to Herceptin. However, no major down-regulation of pHER2 and 
HER2 on cells treated with Herceptin-MNC was observed. Eventually, Herceptin-MNC was 
shown to decrease the activity of prosurvival Akt without down-regulation of the Akt protein. 
Since catalase was capable of reverting the effect of Herceptin-MNC on pAkt, it suggested 
that ROS pathway played a role in down-regulation of Akt activity and hence PI3K pathway. 
In the following chapter, the anticancer effect of Herceptin-MNC would be assessed 
in a tumor xenograft model. 
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Chapter 5 – In Vivo Study of Herceptin Micellar Nanocomplexes 
with Synergistic Therapeutic Effect 
 
5.1. Introduction 
In the previous chapter, we have demonstrated that Herceptin-MNC showed high 
growth inhibitory effect on various HER2-overexpressing cell lines in vitro by the synergistic 
effect of Herceptin and the EGCG derivatives carrier. To evaluate the tumor growth 
inhibition effect of Herceptin-MNC in vivo, we developed a BT-474 tumor xenograft model. 
An ideal therapeutic carrier system should meet certain criteria. The system should be 
able to: (1) encapsulate and protect the therapeutic from degradation; (2) deliver the 
therapeutic to the desired site; and (3) release the therapeutic at the desired site. Our core-
shell micellar nanocomplex (MNC) carrier is comprised of two EGCG derivatives (i.e. 
OEGCG and PEG-EGCG) binding to proteins (e.g. Herceptin) in a spatially ordered structure. 
Herceptin MNC with core-shell structure is formed through self-assembly of 
Herceptin/OEGCG complex and PEG-EGCG. This structure protects Herceptin from 
degradation. The tailored nanosize (< 100 nm) and hydrophilic PEG shell avoid rapid renal 
clearance and proteolysis by reticuloendothelial system (RES) uptake, leading to longer 
circulation time in vivo [39, 49]. It is well known that tumor tissues are served by leaky 
vasculature and poor lymphatic drainage which allow accumulation of particles ranging from 
10 to 500 nm in size, termed as enhanced permeability and retention effect [137, 160]. Our 
tailored nanosize (~ 100 nm) MNC, coupled with long circulation in vivo should enable 
delivery and accumulation of the therapeutics at the tumor site. 
This chapter is the result of a collaborative effort of our lab with Dr. Hak Soo Choi‟s 
research group in Harvard Medical School.  Here, we demonstrate that Herceptin-MNC 
retard the growth of BT-474 xenograft tumor in mice. Histological analysis of the treated 
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tumor samples was performed to understand the in vivo anticancer effect of Herceptin-MNC. 
To study the biodistribution and pharmacokinetic of Herceptin-MNC, Herceptin-MNC was 
formulated using Heptamethine near-infrared (NIR) fluorophore conjugated Herceptin. The 
NIR fluorophore conjugated Herceptin and Herceptin-MNC were intravenously (i.v.) injected 
to tumor bearing mice and imaged for their accumulation and elimination in vivo. 
 
5.2. Materials and methods 
5.2.1. Cell culture 
BT-474 (HTB-20) cells were purchased from ATCC (USA). BT-474 were cultured in 
RPMI 1640 with HEPES buffer, supplemented with 10% Fetal Bovine Serum (FBS) and 100 
units/ml of penicillin and streptomycin. The media and supplements were purchased from 
Gibco. Human umbilical vein endothelial cells (HUVECs) and endothelial growth medium 
(EGM-2) BulletKit were purchased from Lonza Bioscience Singapore. HUVECs were 
maintained in EGM-2 BulletKit supplemented with 10% FBS and 100 units/ml of penicillin 
and streptomycin. Both cell types were maintained at 37 °C in 5% CO2. Media were replaced 
every 2–3 days and the cells were subcultured at 80% confluency. HUVECs at passage 3 
were used in this study. 
 
5.2.2. Tumor regression study 
Balb/cOlaHsd-Foxn1-nu female mice (Harlan, UK) were inoculated subcutaneously 
(s.c.) with 1×10
7
 BT-474 cells suspended in 100 μl of PBS and 120 μl of Matrigel (BD 
Bioscience) at the right flank. One day prior to inoculation, 17β-estradiol pellets (0.72 mg, 
60-day release, Innovative Research of America) were implanted s.c. in each mouse using a 
trocar. Tumors were measured twice weekly with a digital caliper, and the tumor volumes 
(mm
3
) were calculated from the formula, volume = (length × width
2
)/2 [161]. Once the 
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tumors reached a volume of 300 mm
3
, 12 mice/group were randomly allocated to different 
treatments. Treatment was administered twice weekly via i.v. injection for 34 days with PBS 
(vehicle control), Herceptin-MNC (Herceptin = 0.5 mg/ml, OEGCG = 24 μg/ml, PEG-EGCG 
= 261 μg/ml), BSA-MNC (with the equivalents of BSA, OEGCG and PEG-EGCG) and 
Herceptin (0.5 mg/ml). The formulations were the same as those employed in the in vitro 
experiments. The tumor volumes, body weight and mice survival were monitored. At the end 
of the tumor regression experiment, the treated mice were sent to Biopolis Shared Facillities 
(BSF) Histopathology laboratory for necropsy. Organs were extracted for histopathological 
examination. Tumors were extracted and stained against Hematoxylin and Eosin (H&E) for 
tumor morphology, Ki67 for cell proliferation and CD34 for microvessels. The care and use 
of laboratory animals were performed according to the approved protocols by the Institutional 
Animal Care and Use Committee (IACUC) at the Biological Resource Centre (BRC) in 
Biopolis, Singapore. 
 
5.2.3. HUVEC angiogenesis assay 
Matrigel (Becton Dickinson) was thawed on ice overnight and spread evenly over 
each well (50 µl) of a 96-well microplate. The plate was incubated at 37 °C for 4 h to allow 
the Matrigel to form gel. HUVECs were seeded at 2.5×10
4
 in 200 µl of media into each well 
The plate containing cells was spun at 500 rpm for 1 min and incubated at 37 °C in 5% CO2 
for 30 min prior to treatment. Cells were treated with EGCG, OEGCG and PEG-EGCG of 
100 μM of EGCG unit concentration and incubated at 37 °C in 5% CO2. The cells were then 
visualized at 4 h, 8 h and 24 h. 
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5.2.4. Bioconjugation of NIR fluorophores 
Heptamethine near-infrared (NIR) fluorophore ZW800-1 was synthesized as 
previously reported by Choi et al.[162]. Herceptin-ZW800-1 (HER-ZW) was prepared in 0.1 
M sodium phosphate buffer (pH 8) by adding 5 equivalents of ZW800-1 to the Herceptin 
solution. To purify the reaction mixture, the isolation of Herceptin-ZW800-1 was performed 
using Bio-Scale Mini Bio-Gel P-6 Desalting columns (Bio-Rad) with 0.05 M phosphate 
buffer as eluent. The conjugated protein fractions were collected and concentrated using spin 
columns (Vivaspin 500, MWCO 50,000). The conjugation ratio was estimated from the ratio 
of extinction coefficients between ZW800-1 (ε772 nm = 249,000 /M.cm) and Herceptin (ε280 nm 
= 225,000 /M.cm) with correction for the 5% of measured absorbance at 280 nm due to 
ZW800-1. Labelling ratio was ~ 1 for HER-ZW conjugates, which was calculated by the 
following formula: 
Labelling ratio = (Abs772 nm/ε772 nm) / [(Abs280 nm - 0.05Abs772 nm)/ε280 nm]. 
 
5.2.5. Real-time intraoperative imaging 
Herceptin or Herceptin-MNC (100 pmol/g) was injected intravenously (i.v.) into 
athymic nu/nu mice with BT-474 human breast tumor on the left flank. Animals were imaged 
at 24 h post-injection using the Fluorescence-Assisted Resection and Exploration (FLARE™) 
real-time intraoperative imaging system [163]. Excitation fluorescence rate for white light 
and 800 nm near-infrared excitation light were 20,000 lux and 10 mW/cm
2
, respectively. The 
fluorescence (FL) and background (BG) intensities of a region of interest (ROI) over each 
organ/tissue were quantified using custom FLARE™ software. The contrast-to-background 
ratio (CBR) was calculated as CBR = (FL - BG)/BG. At least five animals were analyzed. 
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5.2.6. Immunohistochemistry and NIR immunofluorescence microscopy 
The tumor tissues were deparaffinised using a Leica autostainer. Antigen retrieval was 
performed using a solution of 10 mM of citric acid and 0.05% of Tween 20. The 
deparaffinised slides were boiled in the appropriate antigen retrieval solution for 20 min. The 
polyclonal rabbit anti-human c-erbB-2 oncoprotein (HER2) primary antibody (Dako) was 
used as 1:50 dilution from the stock solution (10 µg/ml) and incubated at 4 °C overnight. 
Goat anti-rabbit secondary antibody labelled with Alexa Fluor 680 (Invitrogen) was 
incubated for 1 h at room temperature at a 250 nM protein concentration. Antibody 
conjugates were fixed in place with 2% paraformaldehyde. The slides were mounted with 
Fluoromount-G and covered with a coverslip for microscopy. Serial sections were H&E 
stained using an autostainer (Leica). NIR fluorescence microscopy was performed on a Nikon 
TE300 with a 4-channel Nikon TE300. The excitation and emission filters used were 650/45 
nm and 710/50 nm for Alexa 680 imaging, and 750/50 nm and 810/40 nm for NIR targeted 
tumor imaging, respectively. 
 
5.2.7. Statistical analysis 
Anticancer effect was analyzed by Student t-test. Mice survival was analyzed by a 
Kaplan-Meier analysis followed by Log Rank Test. p < 0.05 was the minimum requirement 
for a statistically significant difference. 
 
5.3. Results and Discussion 
5.3.1. Tumor regression study 
The anticancer effect of Herceptin-MNC was investigated and compared to that of 
Herceptin and BSA-MNC using a BT-474-xenografted nude mouse model (Figure 5-1a). The 
tumor treated with PBS (vehicle control) progressed rapidly for 34 days. BSA-MNC did not 
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show any tumor growth retardation effect, while Herceptin treated tumor slowed down its 
growth. In contrast, Herceptin-MNC efficiently retarded tumor growth; in fact, complete 
tumor regression was observed in some mice. Herceptin-MNC showed a significantly higher 
anticancer effect than Herceptin.  
During the period of treatment, the animals did not show loss in body weight (Figure 
5-1b), signs of wasting or other visible signs of toxicity e.g. lethargy, diarrhoea, loss of 
mobility and abnormality of activity. This is supported by histopathological findings on the 
mice at the end of the treatment period whereby the examined organs were normal (Table 
5-1). There was also no significant difference in the mortality rate between groups (Figure 
5-1c). The results demonstrated the significant benefit of utilizing Herceptin-MNC in the BT-
474 tumor xenograft model, which could be attributed to the effects of combining Herceptin 
and the green tea-based MNC. 
 
Table 5-1 Pathological findings after administration of Herceptin or Herceptin-MNC 
 Organs Control Herceptin Herceptin-MNC  
 Brain N N N  
 Lung N N N  
 Heart N N N  
 Kidneys N N N  
 Liver N N N  
 Gallbladder N N N  
 Spleen N N N  
Changes of each organ of the mice were determined microscopically 34 days after the 
administration of Herceptin (2.5 mg/kg) or Herceptin-MNC in an equivalent amount to 
Herceptin. N: Normal 
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Figure 5-1 Anticancer effect of Herceptin-MNC in vivo. Treatment was administered 
twice weekly via i.v. injection for 34 days. a, Tumor volumes of BT-474 xenografted nude 
mice. b, Relative body weight change of the mice during treatment. c, Mice survival during 
treatment.  Comparisons between groups were made using a Kaplan-Meier analysis followed 
by the Log Rank Test. PBS (vehicle control, white circles), free Herceptin (white squares), 
BSA-MNC (drug-free carrier, white triangles) and Herceptin-MNC (black circles), n = 12. 
*Significant difference between Herceptin and Herceptin-MNC (p < 0.05). **Significant 
difference between control and Herceptin-MNC (p < 0.001). (mean ± s.e.m.). 
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5.3.2. Histological and immunohistochemical analysis 
At the end of the treatment for the tumor regression study, the tumor bearing mice 
were euthanized and tumors extracted for histological analysis. We observed a marked 
decrease in the cell density for tumors treated with Herceptin-MNC, BSA-MNC and 
Herceptin, which could be resulting from cell proliferation inhibition or induction of cell 
death (Figure 5-2). To further investigate the cause of lower cell density in the treated cells, 
tumor samples were stained for Ki67 and TUNEL. Ki67 is a cellular marker for proliferation 
while terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is an 
apoptosis marker. Ki67 tumor stainings showed that tumors treated with Herceptin-MNC 
showed low cell proliferation as compared to control (untreated tumor), Herceptin and BSA-
MNC. Figure 5-2 shows low TUNEL positive cells on all of the tumor samples, which 
indicated only few apoptotic cells in any of the treatment groups. These results suggested that 
Herceptin-MNC effectively inhibited cell proliferation in the BT-474 tumor xenograft. 
Both Herceptin and EGCG are known to possess anti-angiogenesis properties. Izumi 
et al. showed that Herceptin induced normalization and regression of the vasculature in an 
experimental human breast tumor that overexpresses HER2 in mice [164]. Jung et al. 
demonstrated that treating nude mice with EGCG resulted in marked inhibition of growth, 
vascularity, and proliferation of human colon cancer xenografts [165]. To investigate if 
Herceptin-MNC induces anti-angiogenesis on tumor xenograft, the tumor samples were 
stained for CD34, an angiogenesis marker (Figure 5-2). Herceptin-treated tumor was shown 
to have less microvessels as compared to control. Notably, Herceptin-MNC and BSA-MNC 
(drug-free carrier) showed lower CD34 positive stainings as compared to both Herceptin and 
control. Our results showed that Herceptin-MNC displayed anti-angiogenesis properties 
contributed by both Herceptin and EGCG derivatives. 
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Figure 5-2 Histological analysis of tumor xenograft. Tumors from the tumor regression 
study were harvested and stained for: Hematoxylin and eosin (H&E) to visualize the 
morphology and cell density of BT-474 cells; Ki67 (cell proliferation marker); TUNEL 
(Terminal deoxynucleotidyl transferase dUTP nick end labeling, apoptosis marker); and 
CD34 (angiogenesis marker).   
 
To further elucidate the inhibition of tumor angiogenesis by EGCG derivatives, we 
performed Human umbilical vein endothelial cells (HUVECs) angiogenesis assay on EGCG, 
OEGCG and PEG-EGCG in vitro. Angiogenesis involves the proliferation, migration, and 
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remodeling of endothelial cells in the process of tube formation. Culture of HUVECs on 
Matrigel, an extract of endothelial basement membrane, results in the formation of 
honeycomb-like structures that simulate tube formation by endothelial cells in vivo [166]. In 
Figure 5-3, control (untreated) cells started to migrate towards the formation of tubular 
structure 4 h after cell seeding. At 8 h and 24 h, HUVECs had completely formed 
honeycomb-like structures. EGCG (25 µM) and PEG-EGCG (25 µM) treatment of HUVECs 
did not cause disruption on the honeycomb formation. In contrast, OEGCG (25 µM) 
treatment of HUVECs resulted in disruption on the honeycomb formation. 
 
 
Figure 5-3 Anti-angiogenesis effect of EGCG derivatives. Human umbilical vein 
endothelial cells (HUVECs) were cultured on Matrigel with control media, EGCG, OEGCG 
and PEG-EGCG and monitored for the tube formation. Scale bars = 500 µm. 
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5.3.3. Biodistribution and pharmacokinetic study 
In collaboration with Asst. Prof. Hak Soo Choi, Harvard Medical School, the 
biodistribution and pharmacokinetics of Herceptin in vivo were studied. Heptamethine near-
infrared (NIR) fluorophore ZW800-1 [162] was conjugated to Herceptin with a labelling ratio 
~ 1. Absorbance and fluorescence emission spectra of fluorophore conjugated Herceptin and 
Herceptin-MNC are shown in Figure 5-4. Heptamethine NIR fuorophore conjugated 
Herceptin and Herceptin-MNC were administered to tumor-bearing mice. At 24 h post-
injection, Herceptin-MNC showed higher accumulation in the tumor (8.4 ± 2.7% ID) than 
other organs (e.g. liver 2.1 ± 1.2% ID, kidney 1.7 ± 0.4% ID and heart  1.3 ± 0.6% ID) and 
tissues (muscle (1.1 ± 0.1% ID)) (Figure 5-5a and b). The selective accumulation in the tumor 
might potentially minimize side effects hazardous to normal organs and tissues.  
Figure 5-5b demonstrates that Herceptin-MNC exhibited higher accumulation in 
tumors at 2.3-fold as compared to Herceptin at 24 h post-injection. It also showed lower 
accumulation of Herceptin-MNC in liver and kidney at approximately 0.3-fold for both as 
compared to Herceptin. This phenomenon could be a result of passive targeting rendered by 
the micellar structure at 100 nm. The higher accumulation of Herceptin when delivered in the 
form of MNC could be one of the contributing factors to greater tumor regression efficacy by 
Herceptin-MNC. 
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Figure 5-4 Bioconjugation of NIR Fluorophores. a, Absorbance spectra of Herceptin 
(dotted line) and Herceptin-ZW800-1 conjugate (solid line) and b,  Gel-filtration 
chromatography (GFC) purification of Herceptin-ZW800-1. Absorbance (solid line) and 
fluorescence emission (dotted line) spectra of c, Herceptin-ZW800-1 and d, Herceptin-
ZW800-1-loaded micellar nanocomplex (Herceptin-ZW800-1-MNC) in PBS, pH 7.4. 
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Figure 5-5 Herceptin biodistribution in mice organs and tissues 24 h post-treatment. a, 
Real-time intraoperative tumor detection using NIR fluorescence. 100 pmol/g of each 
compound was injected intravenously into athymic nu/nu mice with HER2-overexpressing 
BT-474 human breast tumors on the left flank. Shown are representative (n = 5) images of 
color video (left), NIR fluorescence (middle), and a pseudocolored merge of the two (right) at 
24 h post-injection. Arrows = Nonspecific binding to liver, kidneys, intestine; Red dotted 
circle = ROI used for TBR background measurement. Also shown is the biodistribution of 
major organs resected 24 h post-injection of NIR dye-conjugated targeting biomolecules. 
Abbreviations used are: T (+), tumor; He, heart; Lu, lung; Li, liver; Pa, pancreas; Sp, spleen; 
Ki, kidneys; Du, duodenum; In, intestine; Mu, muscle. All NIR fluorescence images have 
identical exposure times. Scale bars = 1 cm. b, Biodistribution analysis by comparing CBR of 
resected organ/tissue. Herceptin (white bars), Herceptin-MNC (black bars), n = 5 (mean ± 
s.e.m.). All NIR fluorescence images have identical exposure times and normalization. *p < 
0.05. 
 
Herceptin-MNC showed significantly longer blood half-life as compared to Herceptin. 
The blood half-life (t1/2α) of Herceptin delivered in the form of MNC was ~ 28-fold higher 
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than Herceptin (Figure 5-6). The long in vivo circulation of Herceptin-MNC is believed to 
have resulted in its higher accumulation in the tumor by passive targeting. 
 
 
Figure 5-6 Blood half-life of NIR fluorophore labeled Herceptin and Herceptin-MNC.  
n = 5 (mean ± s. e. m.), *p < 0.001. 
 
The intratumoral microdistribution of Herceptin-MNC was examined to study 
extravasation and penetration of Herceptin-MNC in tumors (Figure 5-7). At 24 h post-
injection, Herceptin-MNC was distributed throughout the tumor tissue co-localising with 
HER2 receptors. One of the challenges in therapeutic delivery was the extravascular barrier 
whereby the delivery system can extravasate but cannot penetrate through the extracellular 
matrix of the tumors [46]. This limited penetration into tumors may limit the efficacy of the 
therapeutics. Our result suggested extravasation and deep tumor penetration of Herceptin-
MNC. 
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Figure 5-7 Herceptin-MNC deep penetration into tumor tissue. H&E staining (left), 
targeted NIR fluorescence (middle, pseudocolored in green), and immunofluorescence 
staining (right, pseudocolored in red) images of BT-474 xenograft tumor at 24 h post-
injection. Scale bars = 100 μm. All NIR fluorescence images have identical exposure times 
and normalization. 
 
5.4. Summary 
Herceptin-MNC showed significantly higher efficiency in retarding the growth of BT-
474 tumor xenografts than the Herceptin treatment alone. Furthermore, Herceptin-MNC did 
not cause observable toxicity and mortality on the mice upon 34 days of treatment. 
Histological and immunohistochemical analysis of treated tumor tissues revealed that 
Herceptin-MNC inhibited cell proliferation and angiogenesis in vivo contributed by both 
Herceptin and the EGCG derivatives carrier.  
In vivo biodistribution analysis revealed high tumor-specific accumulation of 
Herceptin-MNC, which potentially minimizes any undesirable effects on the normal 
organs/tissues. The delivery and accumulation of Herceptin-MNC in the tumor was 2.3-fold 
higher than Herceptin treatment alone. Herceptin-MNC demonstrated a ~ 28-fold higher 
blood half-life (t1/2β) than Herceptin. The long in vivo circulation of Herceptin-MNC is 
believed to have resulted in its higher accumulation in the tumor by EPR effect. Herceptin-
MNC was shown to be distributed throughout the tumor tissue co-localising with HER2 
receptors, suggesting extravasation and deep tumor penetration of Herceptin-MNC. 
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Chapter 6 – Conclusion and Future Perspectives 
 
6.1. Conclusion 
The aim of this project was to develop a nanocarrier system utilizing the green tea 
catechins to deliver therapeutic proteins to the site of interest with the intention of achieving a 
synergistic effect due to the therapeutic proteins and the green tea catechins carriers. The 
approach of the project was to design and develop a self-assembled core-shell micellar 
nanocomplex (MNC) comprising of two EGCG derivatives (i.e. OEGCG and PEG-EGCG) 
and an anticancer monoclonal antibody (e.g. Herceptin (trastuzumab)) for the treatment of 
HER2-overexpressing cancers. 
Towards achieving the aim, EGCG derivatives (i.e. oligomerized EGCG (OEGCG) 
and poly(ethylene glycol)-EGCG conjugated (PEG-EGCG)) were successfully synthesized 
by Baeyer reaction between an aldehyde functinal group and A ring of EGCG. The 
polyphenol-protein interaction was investigated using OEGCG and proteins i.e. bovine serum 
albumin (BSA) and Herceptin (trastuzumab). Herceptin is an FDA approved humanized 
monoclonal antibody targeting the extracellular domain of HER2 for the treatment of 
metastatic breast cancer. OEGCG interacted with the proteins mainly by hydrophobic 
interactions. The interaction of OEGCG with the proteins was dependent upon various 
characteristics of the proteins such as molecular weight and amino acid compositions. Our 
findings suggested that OEGCG formed strong interactions and hence larger complexes with 
proteins having high aromatic rings, high proline content as well as high molecular weight. 
The complexation between OEGCG and proteins was also influenced by various factors 
which affect the hydrophobic interaction such as temperature, pH and ionic strength. 
Complexation of protein with OEGCG did not alter the conformation of the protein 
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indicating preservation of protein activity, which is an important requirement for the use of 
OEGCG as protein carrier for drug delivery. 
With careful consideration, we have formulated a MNC comprising of three 
components: protein, OEGCG and PEG-EGCG. The MNC was constructed by two-step self-
assemblies yielding monodispersed spherical complexes of ~ 90 nm in hydrodynamic 
diameter. Each component of the MNC played an important role in the formation of the 
complex as well as realizing its high therapeutic efficacy. In our current Herceptin-MNC 
system, OEGCG stabilizes the system and exerts its therapeutic efficacy while PEG-EGCG 
confers stealthness to the system as well as contributing to its therapeutic efficacy. Herceptin-
MNC was shown to possess high stability over time and dilution and protect Herceptin from 
enzymatic degradation. 
Our investigations on the carrier system in vitro revealed that EGCG derivatives (i.e. 
OEGCG and PEG-EGCG) selectively inhibited the growth of cancer cells but not normal 
cells. After careful optimization of the compositions of Herceptin-MNC in vitro, the final 
composition to be studied further was fixed as Herceptin = 0.5 mg/ml, OEGCG = 24 µg/ml 
(50 µM EGCG unit concentration) and PEG-EGCG = 261 µg/ml (100 µM EGCG unit 
concentration). At this composition, Herceptin-MNC showed significantly higher growth 
inhibition on various HER2-overexpressing cancer cell lines (i.e. BT-474 (human breast 
cancer cell line), SKBR-3 (human breast cancer cell line) and SKOV-3 (human ovarian 
cancer cell line)) than Herceptin alone. The MNC did not show any toxicity on non HER2-
overexpressing normal cell lines (i.e. MCF-10A (human mammary epithelial cell line) and 
HMEC (human mammary epithelial cells)). The high cell growth inhibitory effect rendered 
by Herceptin-MNC on HER2-overexpressing cell lines was resulted from the synergism 
between Herceptin and EGCG derivatives carriers as indicated by combination index (CI) < 1. 
Chapter 6: Conclusion and future perspectives 
 
 116 
 
Our findings suggested that Herceptin-MNC exerted its anticancer effect via multiple 
molecular mechanisms of Herceptin and EGCG derivatives or in combination. Firstly, EGCG 
derivatives induced EGCG-mediated hydrogen peroxide (H2O2) cytotoxicity on the cells via 
the reactive oxygen species (ROS) pathway. ROS are known to produce oxidative stress and 
cause damage to DNA and other cellular molecules [147, 148]. Secondly, both Herceptin and 
EGCG derivatives induced cell cycle arrest on BT-474 cells. Thirdly, both Herceptin and 
EGCG derivatives specifically PEG-EGCG decreased the signaling of Akt without affecting 
its total expression. And catalase was shown to revert the effect of PEG-EGCG on 
phosphorylated Akt, suggesting the involvement of ROS pathway in down-regulation of Akt 
signaling and hence PI3K pathway. 
In tumor xenograft model on mice, Herceptin-MNC showed significantly higher 
tumor growth retardation efficiency as compared to Herceptin treatment. Herceptin-MNC did 
not cause observable toxicity and mortality in the mice upon 34 days of treatment. 
Histological and immunohistochemical analysis of treated tumor tissues revealed that 
Herceptin-MNC inhibited cell proliferation and angiogenesis in vivo, contributed by both 
Herceptin and EGCG derivatives carrier. Biodistribution and pharmacokinetic study revealed 
the benefits of our core-shell micellar design. The biodistribution analysis revealed high 
tumor-specific accumulation of Herceptin-MNC minimizing any possible undesirable effects 
on the normal organs/tissues. The delivery and accumulation of Herceptin-MNC in the tumor 
was 2.3-fold that of Herceptin alone treatment. Pharmacokinetics study showed a 
significantly higher blood half-life (t1/2β) of Herceptin-MNC than Herceptin treatment at ~ 28-
fold. The long in vivo circulation of Herceptin-MNC is believed to have resulted in its higher 
accumulation in the tumor by EPR effect. Herceptin-MNC was shown to be distributed 
throughout the tumor tissue co-localising with HER2 receptors, suggesting extravasation and 
deep tumor penetration of Herceptin-MNC. 
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We have successfully developed a novel green tea-based micellar nanocomplex 
(MNC) protein delivery system which could offer improved delivery to provide a greatly 
enhanced therapeutic effect associated with combining therapeutic agents with the green tea-
based carrier, as well as the benefits presented by a nanoparticle delivery system. 
 
6.2. Recommendations 
In order to achieve greater therapeutic efficacy, further optimization and modification 
to the current micellar nanocomplex (MNC) system can be explored. Since the MNC system 
is a three-component system i.e. protein, OEGCG and PEG-EGCG, altering either one of the 
components can open up a new area of study. 
Altering protein. Herceptin, known for its long plasma half-life, might not have been 
the most optimal therapeutic to demonstrate the benefits rendered by our micellar drug 
delivery system. Since EGCG can bind to various biological molecules, it makes the MNC a 
versatile system to deliver various therapeutics such as peptides and hydrophobic low-
molecular weight agents, for the treatment of various diseases, not limited to cancer therapy. 
The improvement of plasma half-life of these therapeutics using our micellar nanocomplexes 
would enhance the treatment efficacy. 
Altering OEGCG. OEGCG being the oligomer of EGCG was designed to enhance 
the binding property to the biological molecules due to multidentative binding sites of 
proximity of EGCG. OEGCG has higher hydrophobicity as compared to its monomer and 
hence demonstrated stronger hydrophobic interaction with Herceptin. This strong 
hydrophobic interaction resulted in a stable complex, which could possibly facilitate cell 
uptake of the complex due to its lipophilic nature. On the other hand, the strong interaction 
could also hinder the dissociation of the complex resulting in a decrease of its therapeutic 
efficacy. Based on our earlier findings, OEGCG was capable of restraining the activities of 
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various proteins by complexation and re-establishing the activities upon dissociation of the 
complexes. Therefore, it is desirable to have better control over the interaction between the 
protein and OEGCG so as to maximize its therapeutic efficacy. The interaction force should 
facilitate dissociation at the site of interest while maintaining its stability over delivery. The 
study could be carried out by molecular weight control of OEGCG as well as varying the 
ratio of OEGCG to protein. 
Altering PEG-EGCG. According to our hypothesis, PEG-EGCG would affect three 
different aspects of the MNC. Firstly, PEG-EGCG chain length and chain structure would 
affect the size of the micelle. Long PEG chain would result in larger micellar size while short 
PEG chain would confer smaller one. Secondly, the degree of hydrophilicity of the MNC 
surface would be influenced by the chain length and chain structure of PEG. Long PEG chain 
would cause higher hydrophilicity as compared to short PEG chain. Thirdly, therapeutic 
efficacy of PEG-EGCG would be highly influenced by its molecular weight and chain 
structure. This would eventually affect its anticancer effect, the half-life of the protein to be 
delivered as well as its biodistribution. PEG molecular weight and chain structure influence 
the pharmacokinetics and biodistribution of the delivery system. Our current finding showed 
that β-phase blood half-life of Herceptin was extended by ~ 28 times when delivered by our 
micellar system utilizing PEG-EGCG (Mw 5 kDa). Herceptin-MNC could be formed by 
using PEG-EGCG of various molecular weights and chain structure e.g. PEG 2 kDa, 10 kDa 
and 20 kDa linear chains and PEG 20 kDa branched chain. 
Two-component MNC system. The MNC could also be simplified to two-
component system by combining OEGCG and PEG-EGCG to poly(ethylene glycol)-
conjugated oligomerized EGCG (PEG-OEGCG). This simplified MNC would allow precise 
control over the ratio between the hydrophobic core (EGCG) and the hydrophilic shell (PEG) 
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and hence better control over the drug encapsulation and dissociation which may affect the 
delivery and cellular uptake. 
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Appendix A 
NMR analysis of OEGCG (DMSO-d6) - courtesy of Dr. Chung Joo Eun  
 
1
H and 
13
C NMR analysis of the product revealed the disappearance of H6 and H8, as well as 
the creation of the methyl and methine carbons of the CH3-CH bridge, respectively, 
demonstrating the condensation of EGCG linked through a CH3-CH bridge at the C6 and C8 
position of the A ring. 
 
1
H NMR:  1.3-1.7 (CHCH3), 2.8 (H4β of C ring), 3.1 (H4α of C ring), 5.0 (H2 of C ring), 
5.4 (H3 of C ring), 6.5 (H2” and 6” of D ring), 6.8 (H2‟ and 6‟ of B ring). 
 
13
C NMR:  20.7 (CHCH3), 26.5 (CHCH3), 30.7 (C4 of C ring), 67.7 (C3 of C ring), 76.7 
(C2 of C ring), 90.2-95.7 (C6 and 8 of A ring), 100.5 (C4a), 106.3 (C2‟ and 6‟ of B ring), 
109.6 (C2” and 6” of D ring), 119.3 (C1” of D ring), 128.5 (C4‟ of B ring), 132.8 (C1‟ of B 
ring), 138.7 (C4” of D ring), 145.4-145.8 (C3‟ and 5‟ of B ring and C3” and 5” of D ring), 
151.4-152.1 (C5 and 7 of A ring and C8a), 165.3 (COO). 
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Appendix B 
MALDI-TOF MS of OEGCG - courtesy of Dr. Chung Joo Eun  
 
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) detected the presence of hexamer with a series of peaks separated by the regular 
incremental mass of an EGCG unit linked by the CH3-CH bridge (m/z = 485 of EGCG-
CHCH3 fragment and m/z = 511 of CH3CH-EGCG-CHCH3 fragment) (Figure B1). The 
molecular weight measured by size exclusion chromatography after acetylation was 3300 
(Mw/Mn = 1.2), also showing the yield of hexamer. MALDI-TOF/TOF analysis further 
proved that the parent peaks were comprised of the same fragments of EGCG molecule 
linked with CH3-CH (m/z = 485 and m/z = 511) (Figure B2).   
 
 
 
Figure B1 MALDI-TOF mass spectrum of OEGCG 
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Figure B2 MALDI-TOF/TOF mass spectrum of OEGCG 
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Appendix C 
NMR analysis of PEG-EGCG (DMSO-d6) - courtesy of Dr. Chung Joo Eun  
 
The linkage between PEG and EGCG was detected by 13C NMR analysis.  
 
1
H NMR: 2.7 (H4β of C ring), 2.9 (H4α of C ring), 3.4-3.7 (CH3O and CH2CH2O of PEG), 
5.0 (H2 of C ring), 5.4 (H3 of C ring), 5.8-5.9 (H6 and 8 of A ring), 6.4 (H2” and 6” of D 
ring), 6.8 (H2‟ and 6‟ of B ring). 
 
13
C NMR: CH of PEG linked to EGCG), 30.6 (C4 of C ring), 57.9 (CH3O of PEG), 
69.7-71.2 (CH2CH2O of PEG), 76.3 (C3 of C ring), 86.3 (C2 of C ring), 94.2-95.3 (C6 and 8 
of A ring), 97.4 (C4a), 105.6 (C2‟ and 6‟ of B ring), 108.7 (C2” and 6” of D ring), 119.3 (C1” 
of D ring), 128.5 (C4‟ of B ring), 132.2 (C1‟ of B ring), 138.4 (C4” of D ring), 145.3-145.5 
(C3‟ and 5‟ of B ring and C3” and 5” of D ring), 153.8-156.4 (C5 and 7 of A ring and C8a), 
165.2 (COO). 
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Appendix D 
ESI-TOF MS of PEG-EGCG - courtesy of Dr. Chung Joo Eun  
 
Electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) was conducted on 
PEG (Fig. D1) and PEG-EGCG (Fig. D2). The m/z difference between two clusters of peaks 
was observed as a PEG repeating unit of 44 for both PEG and PEG-EGCG, taking into 
account of a charge of +5 calculated from 0.2 m/z difference between each peak (i.e. 
(1037.26 - 1028.43) × 5 = 44.15). However, the peaks of PEG-EGCG shifted higher with 
molecular weight of two EGCG (i.e. (1211.09 - 1028.65) × 5 = 912.36), as compared to those 
of PEG, demonstrating that the product had two molecules of EGCG bound to an end of the 
PEG chain. 
 
 
 
Figure D1 ESI-TOF mass spectrum of PEG. Zoom-in spectra of +5 charged fragments 
of PEG. 
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Figure D2 ESI-TOF mass spectrum of PEG-EGCG. Zoom-in spectra of +5 charged 
fragments of PEG-EGCG. 
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Appendix E 
TEM Images of Herceptin/OEGCG complex 
 
 
Figure E1 TEM images of Herceptin/OEGCG complex (Herceptin = 0.5 mg/ml, 
OEGCG = 24 µg/ml). Secondary association multiple nuclei of Herceptin/OEGCG complex 
took place. 
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Appendix F 
In vitro optimization of Herceptin-MNC 
 
 
Figure G1 Cell growth inhibitory effect of various formulations of Herceptin-MNC and 
BSA-MNC on BT-474 breast cancer cells. Herceptin-MNC (Herceptin = 0.5 mg/ml, 
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OEGCG = 25 - 300 mM EGCG unit concentration (= 12 - 146 µg/ml), PEG-EGCG = 25 - 
300 mM EGCG unit concentration (65 - 783 µg/ml)) and BSA-MNC (BSA = 0.5 mg/ml, 
equivalent OEGCG and PEG-EGCG concentrations). In each graph, Herceptin-MNC and 
BSA-MNC were made up of Herceptin or BSA and OEGCG at a fixed concentration and 
varying PEG-EGCG. Herceptin and BSA were kept at a constant 0.5 mg/ml for the 
optimization study. Concentration of OEGCG at a, 25 mM, b, 50 mM, c, 100 mM, d, 200 
mM and e, 300 mM EGCG unit concentrations. The data points represent mean values and 
the error bars represent s.d. (n = 4). Herceptin-MNC and BSA-MNC were significantly 
different with p < 0.001 except for the data point marked ** p < 0.01. 
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Appendix G 
Immunofluorescence staining of HER-2 
 
 
Figure G1 Immunofluorescence staining of HER2 upon 4 h, 8 h and 24 h treatment. 
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Appendix H 
Immunofluorescence staining of phosphorylated Akt 
 
 
Figure H1 Immunofluorescence staining of pAkt (S473) 
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